https://trial.medpath.com/news/genmab-discontinues-phase-iii-lung-cancer-bispecific-antibody-acasunlimab-to-focus-on-late-stage-pipeline 2025-12-08T13:26:42+00:00 hourly 0.9 https://trial.medpath.com/news/poolbeg-pharma-s-polb-001-takes-center-stage-in-ps3-4-million-crs-prevention-research-programme 2025-12-08T13:26:39+00:00 hourly 0.9 https://trial.medpath.com/news/anuh-pharma-secures-european-regulatory-approval-for-veterinary-antibiotic-sulfadimethoxine 2025-12-08T13:26:20+00:00 hourly 0.9 https://trial.medpath.com/news/cloudbreak-therapeutics-advances-cbt-004-to-phase-3-trials-following-successful-fda-meeting-for-vascularized-pinguecula-treatment 2025-12-08T09:29:46+00:00 hourly 0.9 https://trial.medpath.com/news/aprea-therapeutics-secures-3-1-million-private-placement-to-advance-cancer-targeting-drug-development 2025-12-08T09:29:35+00:00 hourly 0.9 https://trial.medpath.com/news/sensorion-s-gene-therapy-sens-501-shows-early-efficacy-signals-in-pediatric-congenital-deafness-trial 2025-12-08T09:28:21+00:00 hourly 0.9 https://trial.medpath.com/news/fanss-study-demonstrates-promising-lung-cancer-detection-rates-in-non-smoking-asian-women 2025-12-08T09:28:13+00:00 hourly 0.9 https://trial.medpath.com/news/victorian-researchers-develop-rna-prime-editing-therapy-for-fanconi-anemia-and-rare-blood-disorders 2025-12-08T09:27:38+00:00 hourly 0.9 https://trial.medpath.com/news/epiendo-s-glasmacinal-shows-promise-in-first-copd-clinical-trial-reduces-neutrophilic-inflammation-without-antimicrobial-resistance 2025-12-08T09:26:13+00:00 hourly 0.9 https://trial.medpath.com/news/ucb-s-fenfluramine-shows-significant-seizure-reduction-in-phase-3-trial-for-cdkl5-deficiency-disorder 2025-12-08T09:26:10+00:00 hourly 0.9 https://trial.medpath.com/news/iaso-bio-s-car-t-therapy-shows-93-8-complete-response-rate-in-high-risk-multiple-myeloma-patients 2025-12-08T09:25:49+00:00 hourly 0.9 https://trial.medpath.com/news/puretech-s-deupirfenidone-receives-fda-backing-for-phase-3-trial-in-idiopathic-pulmonary-fibrosis 2025-12-08T09:25:18+00:00 hourly 0.9 https://trial.medpath.com/news/chugai-s-vabysmo-demonstrates-sustained-vision-improvements-in-48-week-angioid-streaks-trial 2025-12-08T09:24:41+00:00 hourly 0.9 https://trial.medpath.com/news/celltrion-internalizes-hyaluronidase-based-subcutaneous-formulation-technology-to-expand-biosimilar-pipeline 2025-12-08T05:27:56+00:00 hourly 0.9 https://trial.medpath.com/news/lower-dose-ipilimumab-shows-superior-efficacy-and-safety-in-advanced-melanoma-treatment 2025-12-08T05:27:47+00:00 hourly 0.9 https://trial.medpath.com/news/imugene-receives-fda-support-for-azer-cel-car-t-therapy-registration-pathway-in-lymphoma 2025-12-08T05:27:12+00:00 hourly 0.9 https://trial.medpath.com/news/ghit-fund-invests-460000-in-novel-mpox-diagnostic-test-development-to-address-african-outbreak 2025-12-08T05:26:48+00:00 hourly 0.9 https://trial.medpath.com/news/chimeric-therapeutics-receives-fda-orphan-drug-designation-for-chm-cdh17-car-t-therapy-in-gastric-cancer 2025-12-08T05:26:45+00:00 hourly 0.9 https://trial.medpath.com/news/leads-biolabs-lbl-034-demonstrates-82-5-response-rate-in-relapsed-refractory-multiple-myeloma-at-ash-2025 2025-12-08T05:25:50+00:00 hourly 0.9 https://trial.medpath.com/news/innovent-s-trispecific-antibody-ibi3003-shows-83-3-response-rate-in-heavily-pretreated-multiple-myeloma-patients 2025-12-08T05:24:54+00:00 hourly 0.9 https://trial.medpath.com/news/iktos-secures-eur1-billion-partnership-with-servier-to-bridge-ai-drug-discovery-with-wet-lab-operations 2025-12-08T03:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/hutchmed-secures-continued-nrdl-coverage-for-three-cancer-drugs-and-gains-commercial-insurance-access-for-tazemetostat-in-china 2025-12-08T01:30:26+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expands-pitolisant-label-to-include-cataplexy-treatment-in-pediatric-narcolepsy-patients 2025-12-08T01:29:40+00:00 hourly 0.9 https://trial.medpath.com/news/dual-bispecific-antibody-combination-achieves-79-response-rate-in-relapsed-refractory-multiple-myeloma-with-extramedullary-disease 2025-12-08T01:29:37+00:00 hourly 0.9 https://trial.medpath.com/news/miltenyi-s-dual-target-car-t-therapy-shows-superior-efficacy-in-pivotal-trial-for-relapsed-large-b-cell-lymphoma 2025-12-08T01:29:26+00:00 hourly 0.9 https://trial.medpath.com/news/smart-stop-trial-shows-targeted-therapy-first-strategy-reduces-chemotherapy-need-in-large-b-cell-lymphoma 2025-12-08T01:29:18+00:00 hourly 0.9 https://trial.medpath.com/news/lynozyfic-monotherapy-shows-promising-efficacy-in-newly-diagnosed-multiple-myeloma-patients 2025-12-08T01:27:24+00:00 hourly 0.9 https://trial.medpath.com/news/structure-therapeutics-to-release-pivotal-data-for-oral-glp-1-obesity-drug-aleniglipron 2025-12-08T01:26:58+00:00 hourly 0.9 https://trial.medpath.com/news/triple-therapy-combination-shows-promise-for-rare-blood-cancer-bpdcn-with-high-response-rates 2025-12-08T01:26:46+00:00 hourly 0.9 https://trial.medpath.com/news/telix-pharmaceuticals-advances-prostact-global-phase-3-trial-with-first-patient-dosed-in-randomized-expansion 2025-12-08T01:26:43+00:00 hourly 0.9 https://trial.medpath.com/news/lyell-s-ronde-cel-shows-93-response-rate-in-large-b-cell-lymphoma-with-enhanced-safety-profile 2025-12-08T01:25:39+00:00 hourly 0.9 https://trial.medpath.com/news/grace-and-molecule-one-partner-to-revolutionize-peptide-manufacturing-with-ai-driven-synthesis-platform 2025-12-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/faron-pharmaceuticals-advances-bexmarilimab-with-new-phase-ii-trial-and-promising-ash-data-in-blood-cancers 2025-12-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/isatuximab-based-therapy-shows-sustained-efficacy-across-age-groups-in-transplant-ineligible-multiple-myeloma 2025-12-07T21:30:03+00:00 hourly 0.9 https://trial.medpath.com/news/aop-health-presents-new-clinical-data-for-ropeginterferon-alfa-2b-in-rare-blood-cancers-at-ash-2025 2025-12-07T21:29:28+00:00 hourly 0.9 https://trial.medpath.com/news/dyne-therapeutics-stock-plunges-17-following-300-million-secondary-offering-despite-dmd-trial-success 2025-12-07T21:29:19+00:00 hourly 0.9 https://trial.medpath.com/news/cenobamate-demonstrates-sustained-efficacy-in-asian-and-chinese-patients-with-focal-seizures 2025-12-07T21:27:57+00:00 hourly 0.9 https://trial.medpath.com/news/msd-pharma-receives-conditional-approval-for-phase-iii-trial-of-sacituzumab-tirumotecan-in-india 2025-12-07T21:27:45+00:00 hourly 0.9 https://trial.medpath.com/news/ideaya-biosciences-completes-enrollment-in-pivotal-uveal-melanoma-trial-advances-novel-adc-program 2025-12-07T21:27:39+00:00 hourly 0.9 https://trial.medpath.com/news/five-day-azacitidine-regimen-shows-superior-survival-outcomes-in-lower-risk-mds-patients 2025-12-07T21:26:42+00:00 hourly 0.9 https://trial.medpath.com/news/hemgenix-gene-therapy-shows-sustained-five-year-efficacy-in-hemophilia-b-patients 2025-12-07T21:26:07+00:00 hourly 0.9 https://trial.medpath.com/news/secura-bio-reports-sustained-efficacy-of-duvelisib-in-heavily-pretreated-peripheral-t-cell-lymphoma-patients 2025-12-07T17:29:45+00:00 hourly 0.9 https://trial.medpath.com/news/zai-lab-secures-reimbursement-renewal-for-three-key-therapies-in-china-s-2025-national-drug-list 2025-12-07T17:28:12+00:00 hourly 0.9 https://trial.medpath.com/news/cellcentric-s-inobrodib-shows-60-75-response-rates-in-heavily-pretreated-multiple-myeloma-patients 2025-12-07T17:25:23+00:00 hourly 0.9 https://trial.medpath.com/news/alx-oncology-s-evorpacept-combination-achieves-92-complete-response-rate-in-frontline-indolent-non-hodgkin-lymphoma-trial 2025-12-07T17:25:12+00:00 hourly 0.9 https://trial.medpath.com/news/bioinvent-s-bi-1808-shows-46-response-rate-in-cutaneous-t-cell-lymphoma-phase-2a-trial 2025-12-07T17:25:06+00:00 hourly 0.9 https://trial.medpath.com/news/prime-medicine-reports-first-in-human-prime-editing-success-for-chronic-granulomatous-disease-in-nejm 2025-12-07T17:25:03+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-incyte-s-first-in-class-mutcalr-targeted-antibody-for-essential-thrombocythemia 2025-12-07T17:24:26+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-incyte-s-inca033989-for-rare-blood-cancer 2025-12-07T17:24:18+00:00 hourly 0.9 https://trial.medpath.com/news/rigel-s-r289-shows-promise-in-lower-risk-mds-with-33-transfusion-independence-rate-at-ash-2025 2025-12-07T17:23:42+00:00 hourly 0.9 https://trial.medpath.com/news/formosa-pharmaceuticals-expands-global-reach-of-fda-approved-eye-surgery-treatment-through-asean-partnership 2025-12-07T13:30:32+00:00 hourly 0.9 https://trial.medpath.com/news/carsgen-s-car-t-therapy-zevor-cel-gains-coverage-under-china-s-new-commercial-health-insurance-catalogue 2025-12-07T13:29:44+00:00 hourly 0.9 https://trial.medpath.com/news/china-s-2025-national-drug-list-adds-114-medicines-with-historic-commercial-insurance-breakthrough 2025-12-07T13:28:53+00:00 hourly 0.9 https://trial.medpath.com/news/china-expands-national-medical-insurance-coverage-with-114-new-drugs-including-50-innovative-pharmaceuticals 2025-12-07T09:26:53+00:00 hourly 0.9 https://trial.medpath.com/news/cdsco-approves-levim-lifetech-s-phase-i-iii-trial-for-teriparatide-biosimilar-in-osteoporosis 2025-12-07T09:26:47+00:00 hourly 0.9 https://trial.medpath.com/news/neurocrine-biosciences-initiates-phase-2a-trial-for-schizophrenia-treatment-following-depression-drug-setback 2025-12-07T09:26:35+00:00 hourly 0.9 https://trial.medpath.com/news/akeso-achieves-complete-nrdl-coverage-for-five-innovative-drugs-in-china-including-first-in-class-bispecifics 2025-12-07T09:26:26+00:00 hourly 0.9 https://trial.medpath.com/news/innovent-secures-nrdl-inclusion-for-seven-innovative-therapies-expanding-access-to-cancer-and-rare-disease-treatments-in-china 2025-12-07T09:26:17+00:00 hourly 0.9 https://trial.medpath.com/news/csl-seqirus-opens-1-billion-cell-based-vaccine-manufacturing-facility-in-melbourne 2025-12-07T05:26:55+00:00 hourly 0.9 https://trial.medpath.com/news/ctdna-testing-outperforms-pet-ct-in-predicting-lymphoma-patient-outcomes 2025-12-07T05:26:46+00:00 hourly 0.9 https://trial.medpath.com/news/akari-therapeutics-initiates-gmp-manufacturing-for-novel-adc-aktx-101-with-wuxi-xdc-partnership 2025-12-07T03:24:54+00:00 hourly 0.9 https://trial.medpath.com/news/once-weekly-oral-hiv-therapy-shows-promise-in-phase-2-trial-maintaining-viral-suppression-through-48-weeks 2025-12-07T01:30:17+00:00 hourly 0.9 https://trial.medpath.com/news/axatilimab-monthly-dosing-shows-promise-for-chronic-gvhd-treatment-convenience 2025-12-07T01:29:42+00:00 hourly 0.9 https://trial.medpath.com/news/star-therapeutics-reports-promising-phase-1-2-data-for-vga039-in-von-willebrand-disease-showing-73-100-reduction-in-bleeding-episodes 2025-12-07T01:26:50+00:00 hourly 0.9 https://trial.medpath.com/news/biontech-and-oncoc4-report-54-reduction-in-death-risk-with-gotistobart-in-advanced-squamous-lung-cancer 2025-12-07T01:26:45+00:00 hourly 0.9 https://trial.medpath.com/news/zenocutuzumab-shows-superior-efficacy-in-treatment-naive-nrg1-nsclc-patients 2025-12-07T01:26:39+00:00 hourly 0.9 https://trial.medpath.com/news/biogen-and-eisai-advance-leqembi-subcutaneous-formulation-with-china-regulatory-milestone 2025-12-07T00:38:00+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-receptor-agonists-linked-to-12-higher-risk-of-chronic-cough-in-large-scale-study 2025-12-06T21:32:31+00:00 hourly 0.9 https://trial.medpath.com/news/fda-recalls-over-11000-bottles-of-blood-pressure-drug-due-to-cholesterol-medication-cross-contamination 2025-12-06T21:32:29+00:00 hourly 0.9 https://trial.medpath.com/news/iv-iron-treatment-improves-survival-in-anemic-patients-with-acute-bacterial-infections-large-scale-study-shows 2025-12-06T21:32:17+00:00 hourly 0.9 https://trial.medpath.com/news/elranatamab-plus-iberdomide-combination-achieves-95-5-response-rate-in-relapsed-refractory-multiple-myeloma 2025-12-06T21:31:40+00:00 hourly 0.9 https://trial.medpath.com/news/disc-medicine-s-disc-0974-shows-promising-results-for-myelofibrosis-anemia-in-phase-2-trial 2025-12-06T21:30:15+00:00 hourly 0.9 https://trial.medpath.com/news/novel-btk-degrader-bgb-16673-demonstrates-85-response-rate-in-heavily-pretreated-cll-sll-patients 2025-12-06T21:30:12+00:00 hourly 0.9 https://trial.medpath.com/news/ash-2025-reveals-critical-gaps-in-sickle-cell-emergency-care-and-promising-gene-therapy-advances 2025-12-06T21:29:52+00:00 hourly 0.9 https://trial.medpath.com/news/prelude-therapeutics-unveils-novel-jak2v617f-selective-inhibitor-and-mcalr-targeted-therapy-for-myeloproliferative-neoplasms 2025-12-06T21:29:50+00:00 hourly 0.9 https://trial.medpath.com/news/lundbeck-s-bexicaserin-shows-sustained-seizure-reduction-in-rare-childhood-epilepsies-after-two-years-of-treatment 2025-12-06T21:29:02+00:00 hourly 0.9 https://trial.medpath.com/news/phase-2-endrad-study-shows-non-tbi-conditioning-maintains-efficacy-in-pediatric-b-all-transplant 2025-12-06T21:28:56+00:00 hourly 0.9 https://trial.medpath.com/news/kite-s-anito-cel-shows-96-response-rate-in-pivotal-multiple-myeloma-trial-supporting-2026-launch-plans 2025-12-06T21:28:54+00:00 hourly 0.9 https://trial.medpath.com/news/natera-acquires-foresight-diagnostics-for-275-million-to-advance-molecular-residual-disease-detection 2025-12-06T21:27:36+00:00 hourly 0.9 https://trial.medpath.com/news/sapablursen-shows-promising-results-in-phase-2a-trial-for-polycythemia-vera-significantly-reducing-phlebotomy-burden 2025-12-06T21:26:08+00:00 hourly 0.9 https://trial.medpath.com/news/states-push-for-fda-approval-of-ibogaine-clinical-trials-to-treat-ptsd-and-opioid-addiction 2025-12-06T21:25:45+00:00 hourly 0.9 https://trial.medpath.com/news/measurable-residual-disease-validated-as-strong-predictor-of-survival-in-aml-patients 2025-12-06T21:25:39+00:00 hourly 0.9 https://trial.medpath.com/news/verona-trial-shows-mixed-results-for-venetoclax-azacitidine-combination-in-high-risk-mds 2025-12-06T21:25:37+00:00 hourly 0.9 https://trial.medpath.com/news/orca-bio-reports-promising-results-for-orca-t-cell-therapy-in-older-blood-cancer-patients-at-ash-2025 2025-12-06T17:36:13+00:00 hourly 0.9 https://trial.medpath.com/news/lisaftoclax-demonstrates-62-5-response-rate-in-btk-refractory-cll-sll-patients 2025-12-06T17:36:11+00:00 hourly 0.9 https://trial.medpath.com/news/large-scale-indian-study-validates-ai-enhanced-smile-laser-technology-for-myopia-correction 2025-12-06T17:35:08+00:00 hourly 0.9 https://trial.medpath.com/news/viatris-divests-815-million-biocon-biologics-stake-to-accelerate-biosimilars-market-re-entry 2025-12-06T17:33:11+00:00 hourly 0.9 https://trial.medpath.com/news/beam-therapeutics-reports-promising-long-term-data-for-base-edited-sickle-cell-therapy-risto-cel 2025-12-06T17:32:31+00:00 hourly 0.9 https://trial.medpath.com/news/kala-bio-completes-10-million-funding-round-to-advance-rare-eye-disease-therapies 2025-12-06T17:31:36+00:00 hourly 0.9 https://trial.medpath.com/news/tirzepatide-demonstrates-94-reduction-in-type-2-diabetes-risk-in-landmark-prevention-trial 2025-12-06T17:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/large-french-study-links-mrna-covid-19-vaccination-to-25-reduction-in-long-term-mortality 2025-12-06T17:29:46+00:00 hourly 0.9 https://trial.medpath.com/news/io-therapeutics-reports-synergistic-activity-of-rxr-agonist-irx4204-with-car-t-therapy-in-multiple-myeloma 2025-12-06T17:29:35+00:00 hourly 0.9 https://trial.medpath.com/news/sync-t-therapy-shows-54-complete-bone-metastasis-resolution-in-phase-1-prostate-cancer-trial 2025-12-06T17:28:35+00:00 hourly 0.9 https://trial.medpath.com/news/arvinas-reports-promising-preclinical-data-for-arv-393-and-glofitamab-combination-in-b-cell-lymphoma 2025-12-06T17:28:30+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-gene-therapy-implementation-shows-promise-for-blood-disorders-despite-timeline-challenges 2025-12-06T17:27:14+00:00 hourly 0.9 https://trial.medpath.com/news/vertex-s-crispr-therapy-casgevy-shows-promise-in-children-as-young-as-5-with-blood-disorders 2025-12-06T17:26:32+00:00 hourly 0.9 https://trial.medpath.com/news/atara-biotherapeutics-approaches-critical-fda-decision-for-tab-cel-as-company-implements-strategic-restructuring 2025-12-06T17:26:29+00:00 hourly 0.9 https://trial.medpath.com/news/cqdm-awards-500000-to-develop-fut8-inhibitors-for-enhanced-cancer-antibody-therapies 2025-12-06T17:25:25+00:00 hourly 0.9 https://trial.medpath.com/news/realta-reports-promising-phase-2-results-for-pegtarazimod-in-steroid-refractory-acute-graft-versus-host-disease 2025-12-06T17:25:23+00:00 hourly 0.9 https://trial.medpath.com/news/deucravacitinib-shows-efficacy-in-psoriasis-patients-who-failed-apremilast-treatment 2025-12-06T17:25:20+00:00 hourly 0.9 https://trial.medpath.com/news/carvykti-shows-durable-treatment-free-remissions-at-2-5-years-in-earlier-line-multiple-myeloma 2025-12-06T17:25:18+00:00 hourly 0.9 https://trial.medpath.com/news/nmdp-access-trial-shows-80-survival-with-mismatched-donor-transplants-expanding-access-for-blood-cancer-patients 2025-12-06T17:25:15+00:00 hourly 0.9 https://trial.medpath.com/news/rusfertide-demonstrates-sustained-efficacy-in-52-week-polycythemia-vera-study-supporting-regulatory-filing 2025-12-06T17:25:10+00:00 hourly 0.9 https://trial.medpath.com/news/genmab-s-epcoritamab-shows-promising-results-in-first-line-lymphoma-treatment-with-fixed-duration-therapy 2025-12-06T17:22:57+00:00 hourly 0.9 https://trial.medpath.com/news/painreform-advances-ocuring-k-phase-2-trial-for-drop-free-post-cataract-surgery-pain-management 2025-12-06T13:25:19+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-reports-positive-phase-3-results-for-migraine-drug-atogepant-in-eclipse-trial 2025-12-06T13:25:17+00:00 hourly 0.9 https://trial.medpath.com/news/lebrikizumab-shows-comparable-efficacy-to-dupilumab-in-moderate-to-severe-atopic-dermatitis-treatment 2025-12-06T13:25:09+00:00 hourly 0.9 https://trial.medpath.com/news/world-s-first-lung-cancer-prevention-vaccine-lungvax-enters-clinical-trials-in-2026 2025-12-06T12:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/toripalimab-achieves-record-breaking-long-term-survival-in-advanced-nasopharyngeal-and-esophageal-cancers 2025-12-06T10:25:30+00:00 hourly 0.9 https://trial.medpath.com/news/uk-launches-controversial-puberty-blocker-trial-following-national-ban 2025-12-06T06:27:44+00:00 hourly 0.9 https://trial.medpath.com/news/india-reopens-pli-applications-for-critical-antibiotic-and-antiviral-drug-manufacturing 2025-12-06T06:25:17+00:00 hourly 0.9 https://trial.medpath.com/news/al-s-pharma-s-ap-101-shows-promising-survival-benefits-in-phase-2-als-trial-advancing-to-phase-3 2025-12-06T04:25:36+00:00 hourly 0.9 https://trial.medpath.com/news/tempramed-expands-temperature-controlled-medication-storage-solutions-across-europe-and-north-america 2025-12-06T04:25:01+00:00 hourly 0.9 https://trial.medpath.com/news/french-study-validates-long-term-safety-and-efficacy-of-moderna-s-covid-19-mrna-vaccine 2025-12-06T01:27:03+00:00 hourly 0.9 https://trial.medpath.com/news/novel-treatment-combinations-show-promise-in-mantle-cell-lymphoma-trials 2025-12-06T01:26:51+00:00 hourly 0.9 https://trial.medpath.com/news/gemcitabine-intravesical-system-shows-promise-in-bcg-unresponsive-bladder-cancer-reducing-need-for-radical-cystectomy 2025-12-06T01:26:19+00:00 hourly 0.9 https://trial.medpath.com/news/berenson-cancer-center-reports-record-13-year-survival-for-multiple-myeloma-patients-without-standard-transplant-therapy 2025-12-06T01:25:08+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-omisirge-as-first-cell-therapy-for-severe-aplastic-anemia 2025-12-06T01:24:36+00:00 hourly 0.9 https://trial.medpath.com/news/hims-hers-enters-canadian-market-through-livewell-acquisition-targeting-generic-semaglutide-launch 2025-12-06T01:24:33+00:00 hourly 0.9 https://trial.medpath.com/news/boehringer-ingelheim-s-digital-therapeutic-ct-155-shows-efficacy-for-schizophrenia-negative-symptoms-in-pivotal-trial 2025-12-06T01:24:27+00:00 hourly 0.9 https://trial.medpath.com/news/amneal-s-crexont-shows-significant-clinical-benefits-in-phase-4-parkinson-s-disease-study 2025-12-05T21:35:45+00:00 hourly 0.9 https://trial.medpath.com/news/perspective-therapeutics-reports-sustained-tumor-response-with-lead-212-radiopharmaceutical-in-neuroendocrine-tumors 2025-12-05T21:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/blueprint-medicines-reports-long-term-efficacy-data-for-ayvakit-in-systemic-mastocytosis-at-ash-2025 2025-12-05T21:34:55+00:00 hourly 0.9 https://trial.medpath.com/news/inmune-bio-s-cordstrom-platform-featured-in-peer-reviewed-study-on-mesenchymal-stromal-cell-therapies 2025-12-05T21:34:21+00:00 hourly 0.9 https://trial.medpath.com/news/apeiron-s-gta182-shows-57-response-rate-in-mtap-deleted-lung-cancer-phase-1-trial 2025-12-05T21:34:07+00:00 hourly 0.9 https://trial.medpath.com/news/freenome-secures-330-million-spac-deal-to-advance-multi-cancer-blood-detection-tests 2025-12-05T21:34:05+00:00 hourly 0.9 https://trial.medpath.com/news/amylyx-reports-positive-safety-data-for-amx0114-in-first-in-human-als-trial 2025-12-05T21:32:29+00:00 hourly 0.9 https://trial.medpath.com/news/imcheck-therapeutics-to-present-promising-ict01-aml-data-at-ash-2025-showing-high-remission-rates-in-first-line-treatment 2025-12-05T21:29:43+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-eighth-denosumab-biosimilar-as-amgen-settles-patent-dispute-with-hikma-and-gedeon-richter 2025-12-05T21:29:38+00:00 hourly 0.9 https://trial.medpath.com/news/amicus-therapeutics-galafold-drives-strong-revenue-growth-amid-pending-4-8b-biomarin-acquisition 2025-12-05T21:29:31+00:00 hourly 0.9 https://trial.medpath.com/news/medicare-part-b-premiums-to-rise-9-7-in-2026-as-cms-negotiates-cancer-drug-price-reductions 2025-12-05T21:28:21+00:00 hourly 0.9 https://trial.medpath.com/news/start-opens-new-early-phase-cancer-clinical-trial-unit-in-new-york-long-island 2025-12-05T21:27:48+00:00 hourly 0.9 https://trial.medpath.com/news/corrixr-therapeutics-partners-to-develop-first-inhaled-crispr-therapy-for-lung-cancer 2025-12-05T21:27:46+00:00 hourly 0.9 https://trial.medpath.com/news/encoded-therapeutics-reports-78-seizure-reduction-with-etx101-gene-therapy-in-dravet-syndrome-trial 2025-12-05T21:27:43+00:00 hourly 0.9 https://trial.medpath.com/news/prostate-cancer-pipeline-shows-robust-growth-with-150-therapies-in-development-across-multiple-companies 2025-12-05T21:27:41+00:00 hourly 0.9 https://trial.medpath.com/news/senores-pharmaceuticals-secures-philippine-fda-approval-for-10-products-across-cardiovascular-cns-and-pain-management-therapies 2025-12-05T21:27:15+00:00 hourly 0.9 https://trial.medpath.com/news/gallop-oncology-s-lyt-200-shows-promising-13-2-month-survival-in-relapsed-refractory-aml-phase-1b-trial 2025-12-05T21:27:03+00:00 hourly 0.9 https://trial.medpath.com/news/spineguard-receives-nmpa-clearance-for-advanced-pediguard-models-in-china 2025-12-05T21:26:58+00:00 hourly 0.9 https://trial.medpath.com/news/oye-therapeutics-receives-fda-clearance-to-begin-clinical-testing-of-novel-caffeine-injection-for-anesthesia-recovery 2025-12-05T21:24:33+00:00 hourly 0.9 https://trial.medpath.com/news/biomea-fusion-s-icovamenib-shows-durable-diabetes-benefits-nine-months-after-treatment-ends 2025-12-05T17:33:47+00:00 hourly 0.9 https://trial.medpath.com/news/medicare-drug-price-negotiations-deliver-major-savings-25-medications-to-see-reduced-costs-by-2027 2025-12-05T17:33:44+00:00 hourly 0.9 https://trial.medpath.com/news/long-term-follow-up-confirms-sustained-benefits-of-adjuvant-pembrolizumab-in-high-risk-clear-cell-renal-cell-carcinoma 2025-12-05T17:31:21+00:00 hourly 0.9 https://trial.medpath.com/news/candel-therapeutics-reports-30-reduction-in-prostate-cancer-recurrence-risk-with-can-2409-in-phase-3-trial 2025-12-05T17:31:19+00:00 hourly 0.9 https://trial.medpath.com/news/first-in-class-mmset-inhibitor-gintemetostat-shows-clinical-activity-in-heavily-pretreated-multiple-myeloma 2025-12-05T17:31:02+00:00 hourly 0.9 https://trial.medpath.com/news/first-ever-personalized-crispr-therapy-successfully-treats-baby-with-ultra-rare-metabolic-disorder 2025-12-05T17:30:33+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-and-tessera-therapeutics-form-global-partnership-to-advance-tsra-196-gene-writing-therapy 2025-12-05T17:30:30+00:00 hourly 0.9 https://trial.medpath.com/news/roche-advances-in-tigit-immunotherapy-and-ai-driven-biomarker-development-signal-strategic-shift-in-precision-oncology 2025-12-05T17:29:58+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-receives-fda-approval-for-oral-wegovy-formulation-driving-pharmaceutical-sector-gains 2025-12-05T17:29:53+00:00 hourly 0.9 https://trial.medpath.com/news/revalia-bio-secures-26-7-million-arpa-h-award-to-revolutionize-drug-development-with-human-data-trials 2025-12-05T17:29:15+00:00 hourly 0.9 https://trial.medpath.com/news/wugen-s-allogeneic-car-t-therapy-shows-promising-long-term-survival-data-in-t-cell-leukemia-patients 2025-12-05T17:29:13+00:00 hourly 0.9 https://trial.medpath.com/news/stat3-inhibitor-safety-concerns-highlight-alternative-approaches-in-ipf-drug-development 2025-12-05T17:29:01+00:00 hourly 0.9 https://trial.medpath.com/news/palbociclib-triple-therapy-shows-significant-survival-benefit-in-her2-positive-breast-cancer-trial 2025-12-05T17:28:20+00:00 hourly 0.9 https://trial.medpath.com/news/fda-launches-commissioner-s-national-priority-voucher-program-to-accelerate-critical-drug-reviews 2025-12-05T17:26:50+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-s-breyanzi-becomes-first-car-t-therapy-approved-for-marginal-zone-lymphoma 2025-12-05T17:26:38+00:00 hourly 0.9 https://trial.medpath.com/news/b-braun-launches-piperacillin-tazobactam-in-duplex-drug-delivery-system-to-reduce-medication-errors 2025-12-05T17:26:07+00:00 hourly 0.9 https://trial.medpath.com/news/otr-therapeutics-secures-100-million-series-a-to-build-capital-efficient-r-d-platform-in-shanghai 2025-12-05T13:32:19+00:00 hourly 0.9 https://trial.medpath.com/news/transcenta-s-osemitamab-combination-shows-promising-16-6-month-median-pfs-in-first-line-gastric-cancer-trial 2025-12-05T13:31:35+00:00 hourly 0.9 https://trial.medpath.com/news/rocatinlimab-demonstrates-significant-efficacy-in-phase-3-trials-for-moderate-to-severe-atopic-dermatitis 2025-12-05T13:31:29+00:00 hourly 0.9 https://trial.medpath.com/news/hanmi-pharmaceutical-s-efeglenatide-receives-fast-track-designation-for-obesity-treatment-in-south-korea 2025-12-05T13:30:13+00:00 hourly 0.9 https://trial.medpath.com/news/cumulus-neuroscience-demonstrates-superior-digital-endpoints-for-alzheimer-s-clinical-trials-at-ctad-2025 2025-12-05T13:30:08+00:00 hourly 0.9 https://trial.medpath.com/news/alvotech-gains-european-approval-for-denosumab-biosimilar-avt03-opening-access-to-1-2-billion-market 2025-12-05T13:29:41+00:00 hourly 0.9 https://trial.medpath.com/news/beigene-reports-record-1-4-billion-quarterly-revenue-as-brukinsa-surpasses-1-billion-milestone 2025-12-05T12:10:43+00:00 hourly 0.9 https://trial.medpath.com/news/annexin-pharmaceuticals-reports-promising-early-results-from-phase-2a-study-of-anxv-in-diabetic-retinopathy-and-retinal-vein-occlusion 2025-12-05T12:10:39+00:00 hourly 0.9 https://trial.medpath.com/news/gelteq-s-oral-gel-platform-shows-22-bioavailability-boost-for-medicinal-cannabinoids-in-preclinical-study 2025-12-05T10:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/us-fda-accepts-wockhardt-s-nda-for-novel-antibiotic-zaynich-marking-historic-first-for-indian-pharma 2025-12-05T09:52:16+00:00 hourly 0.9 https://trial.medpath.com/news/lupin-receives-tentative-fda-approval-for-generic-siponimod-multiple-sclerosis-treatment 2025-12-05T09:52:01+00:00 hourly 0.9 https://trial.medpath.com/news/french-study-of-28-million-adults-confirms-long-term-safety-of-covid-19-mrna-vaccines 2025-12-05T06:09:57+00:00 hourly 0.9 https://trial.medpath.com/news/genentech-and-roche-secure-upc-evidence-orders-against-organon-s-pertuzumab-biosimilar 2025-12-05T06:09:54+00:00 hourly 0.9 https://trial.medpath.com/news/german-court-blocks-merck-s-subcutaneous-keytruda-launch-in-patent-dispute-with-halozyme 2025-12-05T06:09:49+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-first-in-class-bispecific-adc-ide034-for-phase-1-trial-in-multiple-solid-tumors 2025-12-05T06:09:41+00:00 hourly 0.9 https://trial.medpath.com/news/cell-and-gene-therapy-investment-plummets-66-as-industry-shifts-to-lower-risk-strategies 2025-12-05T06:09:38+00:00 hourly 0.9 https://trial.medpath.com/news/ipsc-therapy-for-parkinson-s-disease-receives-fda-rmat-designation-marking-regulatory-milestone 2025-12-05T06:09:30+00:00 hourly 0.9 https://trial.medpath.com/news/cystic-fibrosis-patients-on-triple-drug-therapy-can-safely-reduce-daily-lung-treatments-multi-site-study-shows 2025-12-05T06:09:25+00:00 hourly 0.9 https://trial.medpath.com/news/ascentage-pharma-receives-fda-and-ema-clearance-for-global-phase-iii-trial-of-olverembatinib-in-philadelphia-chromosome-positive-all 2025-12-05T04:09:57+00:00 hourly 0.9 https://trial.medpath.com/news/pharmaceutical-industry-turns-to-ai-to-combat-236-billion-patent-cliff-crisis 2025-12-05T04:09:44+00:00 hourly 0.9 https://trial.medpath.com/news/ai-transforms-cancer-drug-development-from-discovery-to-clinical-management 2025-12-05T03:52:07+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-secures-dual-eu-approvals-dupixent-for-chronic-urticaria-and-first-ever-btk-inhibitor-wayrilz-for-immune-thrombocytopenia 2025-12-05T00:54:41+00:00 hourly 0.9 https://trial.medpath.com/news/fda-lifts-clinical-hold-on-tradipitant-clearing-path-for-first-new-motion-sickness-treatment-in-40-years 2025-12-05T00:54:08+00:00 hourly 0.9 https://trial.medpath.com/news/immorta-bio-s-senovaxtm-shows-tumor-reduction-across-multiple-cancer-types-in-preclinical-study 2025-12-05T00:53:28+00:00 hourly 0.9 https://trial.medpath.com/news/scineuro-pharmaceuticals-secures-53m-series-funding-to-advance-neurodegeneration-therapies 2025-12-05T00:51:02+00:00 hourly 0.9 https://trial.medpath.com/news/nikon-instruments-and-yamaha-motor-form-strategic-partnership-to-advance-drug-discovery-research 2025-12-05T00:50:56+00:00 hourly 0.9 https://trial.medpath.com/news/duchenne-muscular-dystrophy-market-reaches-2-15-billion-as-pipeline-shows-promise-with-75-active-therapies 2025-12-05T00:50:54+00:00 hourly 0.9 https://trial.medpath.com/news/belite-bio-raises-350-million-in-public-offering-to-advance-stargardt-disease-treatment 2025-12-05T00:50:50+00:00 hourly 0.9 https://trial.medpath.com/news/foundation-medicine-reaches-historic-100-companion-diagnostic-approvals-milestone 2025-12-05T00:50:39+00:00 hourly 0.9 https://trial.medpath.com/news/praxis-precision-medicines-advances-two-cns-programs-with-positive-fda-meeting-and-phase-2-results 2025-12-05T00:50:36+00:00 hourly 0.9 https://trial.medpath.com/news/praxis-precision-medicines-reports-positive-embold-study-results-for-relutrigine-in-rare-epileptic-encephalopathies 2025-12-05T00:50:33+00:00 hourly 0.9 https://trial.medpath.com/news/immortal-dragons-invests-in-etheros-pharmaceuticals-catalytic-antioxidant-platform-for-age-related-diseases 2025-12-05T00:50:18+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-breyanzi-car-t-cell-therapy-for-relapsed-refractory-marginal-zone-lymphoma 2025-12-05T00:48:28+00:00 hourly 0.9 https://trial.medpath.com/news/algorae-pharmaceuticals-validates-ai-drug-discovery-platform-and-identifies-90-new-cannabidiol-combination-candidates 2025-12-05T00:48:22+00:00 hourly 0.9 https://trial.medpath.com/news/ossium-health-reports-promising-early-results-for-deceased-donor-bone-marrow-transplants-in-hematologic-malignancies 2025-12-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-advisory-panel-unanimously-rejects-johnson-johnson-s-v-wave-heart-shunt-for-heart-failure 2025-12-04T21:32:06+00:00 hourly 0.9 https://trial.medpath.com/news/cdc-vaccine-advisory-committee-delays-vote-on-hepatitis-b-birth-dose-recommendation 2025-12-04T21:31:43+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-s-mounjaro-gains-insurance-coverage-in-china-and-south-korea-expanding-global-access 2025-12-04T21:31:06+00:00 hourly 0.9 https://trial.medpath.com/news/sglt-2-inhibitors-and-glp-1-agonists-show-promise-in-slowing-frailty-progression-in-older-diabetic-adults 2025-12-04T21:31:03+00:00 hourly 0.9 https://trial.medpath.com/news/paxg-chemotherapy-shows-superior-event-free-survival-over-mfolfirinox-in-pancreatic-cancer-trial 2025-12-04T21:30:44+00:00 hourly 0.9 https://trial.medpath.com/news/dart-trial-shows-combination-immunotherapy-effective-in-rare-cancer-patients-with-brain-metastases 2025-12-04T21:30:08+00:00 hourly 0.9 https://trial.medpath.com/news/absci-initiates-first-in-human-trial-of-ai-designed-antibody-abs-201-for-hair-loss-treatment 2025-12-04T21:29:02+00:00 hourly 0.9 https://trial.medpath.com/news/regeneration-biomedical-s-autologous-stem-cell-therapy-for-alzheimer-s-disease-advances-to-phase-2-following-positive-safety-data 2025-12-04T21:28:59+00:00 hourly 0.9 https://trial.medpath.com/news/rare-pediatric-disease-voucher-program-faces-uncertain-future-as-congressional-reauthorization-stalls 2025-12-04T21:28:38+00:00 hourly 0.9 https://trial.medpath.com/news/port-delivery-system-demonstrates-7-year-vision-preservation-in-wet-amd-patients 2025-12-04T21:28:13+00:00 hourly 0.9 https://trial.medpath.com/news/cedars-sinai-scientists-develop-first-in-class-rna-drug-ty1-to-repair-dna-and-regenerate-damaged-heart-tissue 2025-12-04T21:27:14+00:00 hourly 0.9 https://trial.medpath.com/news/quotient-sciences-and-intrepid-labs-form-strategic-partnership-to-accelerate-ai-guided-drug-formulation-development 2025-12-04T21:25:59+00:00 hourly 0.9 https://trial.medpath.com/news/protara-s-tara-002-cell-therapy-achieves-72-complete-response-rate-in-bcg-naive-bladder-cancer-patients 2025-12-04T21:25:51+00:00 hourly 0.9 https://trial.medpath.com/news/sana-biotechnology-refocuses-pipeline-on-type-1-diabetes-treatment-sc451-and-car-t-platform 2025-12-04T21:25:46+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-data-shows-lecanemab-could-delay-alzheimer-s-progression-by-8-3-years 2025-12-04T21:24:24+00:00 hourly 0.9 https://trial.medpath.com/news/cu-anschutz-launches-first-in-class-phase-1-trial-combining-parp-inhibitor-with-novel-wnt-pathway-modulator-for-resistant-ovarian-cancer 2025-12-04T21:23:48+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-conditional-approval-to-merck-s-exzolt-cattle-ca1-for-new-world-screwworm-prevention-and-treatment 2025-12-04T21:23:45+00:00 hourly 0.9 https://trial.medpath.com/news/als-association-awards-2-million-to-fund-phase-1-trials-of-two-novel-als-therapies 2025-12-04T21:23:37+00:00 hourly 0.9 https://trial.medpath.com/news/magnetically-controlled-microrobots-show-promise-for-precision-drug-delivery-in-preclinical-studies 2025-12-04T17:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/mission-bio-s-single-cell-platform-advances-biomarker-analysis-for-incyte-s-mpn-therapy-at-ash-2025 2025-12-04T17:36:52+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-updated-patient-focused-drug-development-guidance-on-clinical-outcome-assessments 2025-12-04T17:35:40+00:00 hourly 0.9 https://trial.medpath.com/news/polyrizon-s-naloxone-hydrogel-shows-superior-nasal-adhesion-in-preclinical-study-potentially-improving-overdose-reversal 2025-12-04T17:35:16+00:00 hourly 0.9 https://trial.medpath.com/news/debiopharm-initiates-phase-iii-trial-for-quarterly-acromegaly-treatment-debio-4126 2025-12-04T17:35:02+00:00 hourly 0.9 https://trial.medpath.com/news/engineered-herpes-virus-shows-promise-against-treatment-resistant-glioblastoma-in-preclinical-studies 2025-12-04T17:34:59+00:00 hourly 0.9 https://trial.medpath.com/news/replicate-bioscience-partners-with-instituto-butantan-to-advance-self-replicating-rna-rabies-vaccine-in-latin-america 2025-12-04T17:33:08+00:00 hourly 0.9 https://trial.medpath.com/news/gt-biopharma-advances-gtb-3650-to-higher-dose-level-in-phase-1-blood-cancer-trial 2025-12-04T17:32:40+00:00 hourly 0.9 https://trial.medpath.com/news/galmed-secures-global-patent-protection-for-aramchol-rezdiffra-combination-therapy-in-mash-treatment 2025-12-04T17:32:33+00:00 hourly 0.9 https://trial.medpath.com/news/luspatercept-shows-survival-advantage-over-esa-in-low-risk-mds-after-three-years 2025-12-04T17:31:26+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-strategy-overcomes-immunotherapy-resistance-in-estrogen-receptor-positive-breast-cancer 2025-12-04T17:31:23+00:00 hourly 0.9 https://trial.medpath.com/news/alpha-9-oncology-initiates-phase-1-trial-of-novel-actinium-225-radiotherapeutic-for-melanoma 2025-12-04T17:29:45+00:00 hourly 0.9 https://trial.medpath.com/news/volitionrx-s-sepsis-biomarker-selected-for-eur6-3-million-french-national-healthcare-initiative 2025-12-04T17:29:37+00:00 hourly 0.9 https://trial.medpath.com/news/jyong-biotech-signs-mou-with-vietnamese-distributor-to-explore-mcs-2-market-entry 2025-12-04T17:29:34+00:00 hourly 0.9 https://trial.medpath.com/news/sctbio-and-fortrea-form-strategic-partnership-to-accelerate-cell-and-gene-therapy-development 2025-12-04T17:29:29+00:00 hourly 0.9 https://trial.medpath.com/news/orano-med-and-roche-advance-novel-two-step-radioimmunotherapy-targeting-cea-positive-cancers 2025-12-04T17:27:26+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-plozasiran-for-familial-chylomicronemia-syndrome-marking-breakthrough-in-rare-lipid-disorder-treatment 2025-12-04T17:26:45+00:00 hourly 0.9 https://trial.medpath.com/news/esperare-secures-gates-foundation-grant-to-develop-novel-preeclampsia-therapy 2025-12-04T17:26:39+00:00 hourly 0.9 https://trial.medpath.com/news/bioage-labs-reports-positive-phase-1-data-for-brain-penetrant-nlrp3-inhibitor-bge-102 2025-12-04T17:26:37+00:00 hourly 0.9 https://trial.medpath.com/news/j-d-pharmaceuticals-receives-fda-orphan-drug-designation-for-hepatocellular-carcinoma-treatment 2025-12-04T17:25:43+00:00 hourly 0.9 https://trial.medpath.com/news/bd-and-chemoglo-partner-to-enhance-hazardous-drug-contamination-testing-in-healthcare-facilities 2025-12-04T17:25:38+00:00 hourly 0.9 https://trial.medpath.com/news/merakris-therapeutics-achieves-fda-alignment-on-mtx-001-development-pathway-for-chronic-venous-leg-ulcers 2025-12-04T17:25:35+00:00 hourly 0.9 https://trial.medpath.com/news/italian-no-cut-trial-shows-nonoperative-management-safe-for-rectal-cancer-patients-after-complete-response 2025-12-04T17:24:56+00:00 hourly 0.9 https://trial.medpath.com/news/microbiota-therapy-maat013-achieves-62-response-rate-in-refractory-gi-agvhd-phase-3-trial 2025-12-04T17:24:51+00:00 hourly 0.9 https://trial.medpath.com/news/fda-proposes-higher-user-fees-for-overseas-phase-i-trials-to-boost-domestic-drug-development 2025-12-04T17:24:23+00:00 hourly 0.9 https://trial.medpath.com/news/malawi-becomes-fourth-african-nation-to-approve-lenacapavir-gilead-s-twice-yearly-hiv-prevention-injectable 2025-12-04T17:24:21+00:00 hourly 0.9 https://trial.medpath.com/news/hope-medicine-s-hmi-115-receives-fda-fast-track-designation-for-endometriosis-pain-treatment 2025-12-04T17:23:48+00:00 hourly 0.9 https://trial.medpath.com/news/paradigm-health-secures-78-million-series-b-to-expand-ai-powered-clinical-trial-platform-across-us-healthcare-systems 2025-12-04T17:21:59+00:00 hourly 0.9 https://trial.medpath.com/news/terasaki-institute-develops-organ-on-chip-platform-to-test-cancer-vaccines-in-aging-populations 2025-12-04T14:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/oral-glp-1-obesity-drugs-set-to-transform-korean-market-as-eli-lilly-and-novo-nordisk-advance-next-generation-therapies 2025-12-04T13:31:30+00:00 hourly 0.9 https://trial.medpath.com/news/brazil-approves-world-s-first-single-dose-dengue-vaccine-following-severe-2024-outbreak 2025-12-04T13:31:22+00:00 hourly 0.9 https://trial.medpath.com/news/denali-therapeutics-secures-275-million-royalty-deal-with-royalty-pharma-for-hunter-syndrome-therapy 2025-12-04T13:30:42+00:00 hourly 0.9 https://trial.medpath.com/news/labgenius-and-sanofi-expand-ai-driven-antibody-partnership-with-new-nanobody-optimization-collaboration 2025-12-04T13:30:36+00:00 hourly 0.9 https://trial.medpath.com/news/kelun-biotech-and-crescent-biopharma-form-strategic-partnership-to-advance-novel-oncology-therapeutics 2025-12-04T13:30:31+00:00 hourly 0.9 https://trial.medpath.com/news/formycon-partners-with-ms-pharma-for-keytruda-biosimilar-fyb206-commercialization-in-mena-region 2025-12-04T13:30:18+00:00 hourly 0.9 https://trial.medpath.com/news/mabxience-and-hp-develop-ai-powered-digital-twin-for-monoclonal-antibody-manufacturing 2025-12-04T13:29:35+00:00 hourly 0.9 https://trial.medpath.com/news/iqvia-partners-with-aws-to-launch-agentic-ai-platform-for-clinical-trial-automation 2025-12-04T13:29:23+00:00 hourly 0.9 https://trial.medpath.com/news/dupilumab-significantly-improves-quality-of-life-in-chronic-spontaneous-urticaria-patients 2025-12-04T13:29:18+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-completes-acquisition-of-vicebio-expanding-respiratory-vaccine-portfolio-with-molecular-clamp-technology 2025-12-04T13:29:06+00:00 hourly 0.9 https://trial.medpath.com/news/oxford-begins-first-in-human-trial-of-lassa-fever-vaccine-using-covid-19-platform-technology 2025-12-04T13:27:57+00:00 hourly 0.9 https://trial.medpath.com/news/laigo-bio-secures-eur11-5-million-to-advance-novel-protein-degradation-platform-for-cancer-and-autoimmune-diseases 2025-12-04T13:27:51+00:00 hourly 0.9 https://trial.medpath.com/news/actithera-appoints-radiopharmaceutical-veteran-dr-darshan-dalal-as-chief-medical-officer-to-lead-fap-targeting-therapy-development 2025-12-04T13:27:46+00:00 hourly 0.9 https://trial.medpath.com/news/monte-rosa-therapeutics-reports-promising-mrt-8102-cardiovascular-data-and-prepares-updated-mrt-2359-cancer-results 2025-12-04T13:27:37+00:00 hourly 0.9 https://trial.medpath.com/news/lupin-partners-with-valorum-biologics-for-us-launch-of-cancer-biosimilar-armlupeg 2025-12-04T13:26:33+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-initiates-phase-iia-trial-for-novel-alport-syndrome-treatment-bay-3401016 2025-12-04T13:26:30+00:00 hourly 0.9 https://trial.medpath.com/news/ionctura-initiates-phase-i-ii-trial-combining-roginolisib-with-ruxolitinib-for-jak-inhibitor-resistant-myelofibrosis 2025-12-04T13:26:05+00:00 hourly 0.9 https://trial.medpath.com/news/garsorasib-shows-45-5-response-rate-in-kras-g12c-mutated-pancreatic-cancer-patients 2025-12-04T13:26:02+00:00 hourly 0.9 https://trial.medpath.com/news/avencell-therapeutics-receives-fda-and-ema-clearance-for-phase-i-ii-trial-of-dual-target-allogeneic-car-t-therapy 2025-12-04T13:25:55+00:00 hourly 0.9 https://trial.medpath.com/news/fda-announces-shift-to-single-trial-standard-for-drug-approvals-under-new-commissioner-makary 2025-12-04T13:25:53+00:00 hourly 0.9 https://trial.medpath.com/news/atavistik-bio-unveils-novel-jak2-v617f-mutant-selective-inhibitors-for-myeloproliferative-neoplasms-at-ash-2025 2025-12-04T12:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/insilico-medicine-raises-295-million-in-hong-kong-ipo-as-ai-drug-discovery-gains-momentum 2025-12-04T11:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-advances-new-approach-methodologies-to-reduce-animal-testing-in-drug-development 2025-12-04T10:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/cms-proposes-major-medicare-advantage-and-part-d-reforms-for-2027-streamlining-star-ratings-and-drug-coverage-programs 2025-12-04T09:26:55+00:00 hourly 0.9 https://trial.medpath.com/news/former-fda-and-cdc-leaders-warn-against-proposed-vaccine-policy-changes-amid-acip-deliberations 2025-12-04T09:26:28+00:00 hourly 0.9 https://trial.medpath.com/news/federal-court-of-appeal-upholds-trademark-injunction-against-samsung-bioepis-byooviz-biosimilar 2025-12-04T09:25:50+00:00 hourly 0.9 https://trial.medpath.com/news/hiropharmaconsulting-receives-japan-s-first-patent-for-ai-enabled-pharmacovigilance-system-validation 2025-12-04T09:25:44+00:00 hourly 0.9 https://trial.medpath.com/news/argenica-s-arg-007-shows-promise-for-severe-stroke-patients-while-demonstrating-safety-compatibility-with-standard-clot-dissolving-therapies 2025-12-04T09:25:41+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-establishes-india-as-largest-r-d-hub-outside-switzerland-with-9000-strong-workforce 2025-12-04T09:25:32+00:00 hourly 0.9 https://trial.medpath.com/news/fda-proposes-major-overhaul-of-biosimilar-approval-process-eliminating-most-clinical-studies 2025-12-04T09:25:26+00:00 hourly 0.9 https://trial.medpath.com/news/liver-cirrhosis-pipeline-shows-strong-growth-with-30-companies-advancing-novel-therapies-through-clinical-trials 2025-12-04T07:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/altimmune-announces-ceo-transition-as-pemvidutide-approaches-phase-3-readiness 2025-12-04T06:40:46+00:00 hourly 0.9 https://trial.medpath.com/news/biontech-completes-curevac-acquisition-with-81-74-shareholder-acceptance-consolidating-mrna-technology-portfolio 2025-12-04T06:39:09+00:00 hourly 0.9 https://trial.medpath.com/news/transthera-s-tinengotinib-receives-priority-review-status-in-china-for-advanced-cholangiocarcinoma-treatment 2025-12-04T06:39:06+00:00 hourly 0.9 https://trial.medpath.com/news/novabridge-s-ragistomig-shows-promise-in-checkpoint-inhibitor-resistant-cancers-with-new-q6w-dosing-schedule 2025-12-04T06:38:47+00:00 hourly 0.9 https://trial.medpath.com/news/vera-therapeutics-reports-positive-phase-3-igan-data-prompting-valuation-reassessment 2025-12-04T06:38:44+00:00 hourly 0.9 https://trial.medpath.com/news/nona-biosciences-appoints-dr-hongjiang-miao-as-chief-ai-officer-to-advance-ai-driven-drug-discovery-strategy 2025-12-04T06:38:30+00:00 hourly 0.9 https://trial.medpath.com/news/impact-biotech-reports-70-complete-response-rate-in-phase-3-enlighted-trial-of-padeliporfin-vtp-for-low-grade-upper-tract-urothelial-cancer 2025-12-04T06:38:22+00:00 hourly 0.9 https://trial.medpath.com/news/celltrion-s-ct-p70-adc-receives-fda-fast-track-designation-for-metastatic-lung-cancer 2025-12-04T06:38:19+00:00 hourly 0.9 https://trial.medpath.com/news/axogen-receives-fda-biologics-license-approval-for-avance-nerve-allograft-marking-regulatory-milestone 2025-12-04T06:37:47+00:00 hourly 0.9 https://trial.medpath.com/news/ucsf-study-shows-promise-for-hiv-functional-cure-through-triple-immunotherapy-approach 2025-12-04T06:37:29+00:00 hourly 0.9 https://trial.medpath.com/news/janx007-demonstrates-promising-efficacy-and-manageable-safety-profile-in-phase-1-metastatic-prostate-cancer-trial 2025-12-04T06:36:58+00:00 hourly 0.9 https://trial.medpath.com/news/exmoor-pharma-and-ucl-form-strategic-partnership-to-accelerate-cell-and-gene-therapy-development 2025-12-04T06:36:24+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-mannkind-s-readyflow-autoinjector-application-for-rapid-furosemide-delivery-in-heart-failure 2025-12-04T06:33:56+00:00 hourly 0.9 https://trial.medpath.com/news/larkspur-biosciences-initiates-first-in-human-trial-of-novel-protein-degrader-lrk-4189-for-colorectal-cancer 2025-12-04T06:33:54+00:00 hourly 0.9 https://trial.medpath.com/news/gensight-biologics-secures-french-regulatory-approvals-for-gs010-lumevoq-gene-therapy-in-rare-blindness-disease 2025-12-04T06:32:19+00:00 hourly 0.9 https://trial.medpath.com/news/lyric-bio-raises-6-6m-to-revolutionize-ivig-production-with-ultra-high-density-bioreactors 2025-12-04T06:32:13+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-launches-phase-iii-trial-testing-mirena-iud-for-precancerous-uterine-condition-with-no-approved-treatments 2025-12-04T06:32:04+00:00 hourly 0.9 https://trial.medpath.com/news/alpha-tau-receives-fda-approval-for-prostate-cancer-trial-and-presents-pancreatic-cancer-data-at-asco 2025-12-04T06:31:44+00:00 hourly 0.9 https://trial.medpath.com/news/tscan-therapeutics-announces-two-year-relapse-data-for-tsc-101-cell-therapy-ahead-of-pivotal-trial-launch 2025-12-04T06:31:09+00:00 hourly 0.9 https://trial.medpath.com/news/dogwood-therapeutics-secures-26-8m-financing-and-files-new-ip-protection-for-synthetic-halneuron-through-2045 2025-12-04T06:30:35+00:00 hourly 0.9 https://trial.medpath.com/news/advanced-solid-dispersion-techniques-show-promise-for-improving-tegoprazan-bioavailability-in-gerd-treatment 2025-12-04T06:30:18+00:00 hourly 0.9 https://trial.medpath.com/news/quralis-demonstrates-target-engagement-of-qrl-101-in-als-patients-advancing-precision-medicine-for-neurological-disorders 2025-12-04T06:29:32+00:00 hourly 0.9 https://trial.medpath.com/news/soligenix-advances-hybryte-through-final-phase-3-trial-for-rare-cutaneous-t-cell-lymphoma 2025-12-04T06:27:28+00:00 hourly 0.9 https://trial.medpath.com/news/immutep-s-eftilagimod-alfa-shows-strong-response-rates-in-metastatic-breast-cancer-establishes-optimal-dose-for-future-trials 2025-12-04T06:27:13+00:00 hourly 0.9 https://trial.medpath.com/news/scholar-rock-faces-manufacturing-setback-as-fda-issues-warning-letter-to-catalent-partner-ahead-of-apitegromab-launch 2025-12-04T06:26:02+00:00 hourly 0.9 https://trial.medpath.com/news/ventyx-expands-phase-2-recurrent-pericarditis-trial-internationally-adds-industry-veterans-to-advisory-board 2025-12-04T06:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/australian-court-rules-formulation-patents-ineligible-for-patent-term-extensions-in-landmark-otsuka-decision 2025-12-04T06:23:09+00:00 hourly 0.9 https://trial.medpath.com/news/major-mid-atlantic-insurer-expands-coverage-for-nerivio-migraine-device-providing-access-to-3-4-million-members 2025-12-04T06:23:06+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-s-cagrisema-outperforms-ozempic-in-diabetes-trial-company-plans-pediatric-obesity-study 2025-12-04T06:23:03+00:00 hourly 0.9 https://trial.medpath.com/news/ovid-therapeutics-reports-first-in-human-safety-data-for-novel-kcc2-direct-activator-ov350 2025-12-04T06:22:55+00:00 hourly 0.9 https://trial.medpath.com/news/next-generation-her2-targeted-adcs-show-promise-in-breast-cancer-trials 2025-12-04T06:20:15+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-s-low-dose-mri-contrast-agent-gadoquatrane-shows-promise-in-pediatric-study 2025-12-04T06:20:04+00:00 hourly 0.9 https://trial.medpath.com/news/lithium-shows-promise-in-suppressing-hiv-reactivation-through-novel-mechanism 2025-12-04T06:19:39+00:00 hourly 0.9 https://trial.medpath.com/news/junevity-raises-20m-to-advance-first-in-class-sirna-cell-reprogramming-therapy-for-metabolic-disorders 2025-12-04T06:16:54+00:00 hourly 0.9 https://trial.medpath.com/news/experimental-vaccine-provides-year-long-protection-against-deadly-allergic-reactions-in-mice 2025-12-04T06:16:40+00:00 hourly 0.9 https://trial.medpath.com/news/aspire-biopharma-advances-sublingual-aspirin-for-heart-attack-treatment-with-fda-pre-ind-submission 2025-12-04T06:15:21+00:00 hourly 0.9 https://trial.medpath.com/news/ultragenyx-advances-multiple-gene-therapies-toward-regulatory-approval-with-dtx401-bla-submission 2025-12-04T06:15:10+00:00 hourly 0.9 https://trial.medpath.com/news/robust-aml-clinical-pipeline-shows-promise-with-100-companies-developing-novel-therapies 2025-12-04T06:14:21+00:00 hourly 0.9 https://trial.medpath.com/news/foresight-diagnostics-showcases-ultrasensitive-mrd-technology-in-multiple-lymphoma-studies-at-ash-2025 2025-12-04T06:14:18+00:00 hourly 0.9 https://trial.medpath.com/news/ge-healthcare-and-mayo-clinic-launch-gemini-rt-initiative-to-transform-personalized-radiation-therapy 2025-12-04T06:14:16+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-evidence-shows-adalimumab-biosimilars-maintain-efficacy-despite-injection-site-tolerability-concerns 2025-12-04T06:13:33+00:00 hourly 0.9 https://trial.medpath.com/news/rentschler-biopharma-and-coriolis-pharma-form-strategic-alliance-to-deliver-integrated-biopharmaceutical-solutions 2025-12-04T06:11:49+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-francis-medical-s-vanquish-water-vapor-system-for-intermediate-risk-prostate-cancer-treatment 2025-12-04T06:10:24+00:00 hourly 0.9 https://trial.medpath.com/news/epcoritamab-demonstrates-strong-efficacy-in-elderly-dlbcl-and-follicular-lymphoma-patients-at-ash-2024 2025-12-04T06:10:19+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-receives-fda-clearance-for-hugo-robotic-surgery-system-in-urology-procedures 2025-12-04T06:09:41+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-to-launch-ozempic-in-india-this-december-as-competition-intensifies-in-150-billion-weight-loss-market 2025-12-04T06:09:05+00:00 hourly 0.9 https://trial.medpath.com/news/uk-clinical-trial-recruitment-drops-25-despite-government-reform-efforts 2025-12-04T06:08:39+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-commits-40-million-to-indiana-university-for-ai-enhanced-clinical-trial-infrastructure 2025-12-04T06:07:21+00:00 hourly 0.9 https://trial.medpath.com/news/arrowhead-pharmaceuticals-receives-fda-breakthrough-therapy-designation-for-plozasiran-in-severe-hypertriglyceridemia 2025-12-04T06:06:39+00:00 hourly 0.9 https://trial.medpath.com/news/fda-reduces-surveillance-requirements-for-seastar-medical-s-pediatric-aki-therapy-following-promising-safety-data 2025-12-04T06:04:25+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-advances-12-billion-acquisition-of-avidity-biosciences-for-rna-therapeutics-platform 2025-12-04T06:04:20+00:00 hourly 0.9 https://trial.medpath.com/news/inovio-pharmaceuticals-completes-bla-submission-for-first-in-class-dna-immunotherapy-ino-3107 2025-12-04T06:03:59+00:00 hourly 0.9 https://trial.medpath.com/news/santen-and-singapore-eye-research-institute-launch-21-million-collaboration-to-develop-disease-modifying-eye-therapies 2025-12-04T06:02:57+00:00 hourly 0.9 https://trial.medpath.com/news/virax-biolabs-advances-post-acute-infection-syndrome-diagnostics-with-completed-uk-trial-recruitment-and-fda-engagement 2025-12-04T06:02:55+00:00 hourly 0.9 https://trial.medpath.com/news/cardiol-therapeutics-cardiolrx-shows-significant-cardiac-benefits-in-phase-ii-myocarditis-trial 2025-12-04T06:02:10+00:00 hourly 0.9 https://trial.medpath.com/news/ltr-pharma-receives-ethics-approval-for-spontan-phase-2-trial-targeting-elderly-erectile-dysfunction-patients 2025-12-04T06:01:56+00:00 hourly 0.9 https://trial.medpath.com/news/hoth-therapeutics-advances-multi-asset-pipeline-with-phase-2-progress-and-orphan-drug-designation 2025-12-04T06:00:58+00:00 hourly 0.9 https://trial.medpath.com/news/acumen-pharmaceuticals-demonstrates-68-fold-increase-in-brain-delivery-for-alzheimer-s-antibody-using-novel-transferrin-receptor-technology 2025-12-04T06:00:52+00:00 hourly 0.9 https://trial.medpath.com/news/renerva-receives-fda-approval-for-first-in-human-trial-of-novel-nerve-capping-device-to-prevent-chronic-amputation-pain 2025-12-04T05:59:08+00:00 hourly 0.9 https://trial.medpath.com/news/aethlon-medical-s-hemopurifier-shows-promise-for-long-covid-treatment-in-preclinical-study 2025-12-04T05:58:50+00:00 hourly 0.9 https://trial.medpath.com/news/inmune-bio-advances-regulatory-pathways-for-cordstrom-and-xpro1595-programs 2025-12-04T05:58:00+00:00 hourly 0.9 https://trial.medpath.com/news/granata-bio-advances-phase-iii-grace-study-for-investigational-gonadotropin-in-ivf-treatment 2025-12-04T05:57:57+00:00 hourly 0.9 https://trial.medpath.com/news/mezzion-secures-key-u-s-patent-for-udenafil-in-fontan-patients-extending-exclusivity-to-early-2040s 2025-12-04T05:57:43+00:00 hourly 0.9 https://trial.medpath.com/news/amplia-therapeutics-secures-u-s-patent-protection-for-fak-inhibitor-narmafotinib-through-2040 2025-12-04T05:56:53+00:00 hourly 0.9 https://trial.medpath.com/news/rondo-therapeutics-initiates-first-in-human-trial-of-rndo-564-novel-bispecific-antibody-for-advanced-solid-tumors 2025-12-04T05:55:39+00:00 hourly 0.9 https://trial.medpath.com/news/archeus-technologies-initiates-first-in-human-trial-of-art-101-psma-targeting-radioligand-therapy-for-metastatic-prostate-cancer 2025-12-04T05:55:33+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-expanded-approval-for-eli-lilly-s-jaypirca-in-earlier-line-cll-sll-treatment 2025-12-04T05:55:30+00:00 hourly 0.9 https://trial.medpath.com/news/sutro-biopharma-initiates-phase-1-trial-of-stro-004-next-generation-tissue-factor-adc-for-advanced-solid-tumors 2025-12-04T05:55:27+00:00 hourly 0.9 https://trial.medpath.com/news/armr-sciences-initiates-first-human-trials-for-fentanyl-vaccine-in-early-2025 2025-12-04T05:54:28+00:00 hourly 0.9 https://trial.medpath.com/news/polypid-receives-fda-support-for-d-plex100-nda-submission-following-positive-pre-nda-meeting 2025-12-04T05:54:25+00:00 hourly 0.9 https://trial.medpath.com/news/muvon-therapeutics-reports-breakthrough-phase-2-results-for-muscle-cell-based-stress-urinary-incontinence-therapy 2025-12-04T05:54:02+00:00 hourly 0.9 https://trial.medpath.com/news/hemophilia-gene-therapies-face-market-struggles-despite-scientific-promise 2025-12-04T05:53:59+00:00 hourly 0.9 https://trial.medpath.com/news/pacira-s-cryoneurolysis-device-shows-superior-pain-relief-over-radiofrequency-ablation-in-chronic-low-back-pain-study 2025-12-04T05:53:23+00:00 hourly 0.9 https://trial.medpath.com/news/ema-grants-conditional-marketing-authorization-for-immunitybio-s-anktiva-in-bladder-cancer 2025-12-04T05:53:18+00:00 hourly 0.9 https://trial.medpath.com/news/natera-s-signatera-shows-superior-performance-in-lymphoma-detection-at-ash-2025 2025-12-04T05:52:34+00:00 hourly 0.9 https://trial.medpath.com/news/strm-bio-secures-8-4m-arpa-h-contract-to-develop-novel-extracellular-vesicle-platform-for-in-vivo-car-t-cell-engineering 2025-12-04T05:49:54+00:00 hourly 0.9 https://trial.medpath.com/news/onco3r-therapeutics-reports-positive-phase-1-data-for-novel-sik3-inhibitor-o3r-5671-in-autoimmune-disease-treatment 2025-12-04T05:49:39+00:00 hourly 0.9 https://trial.medpath.com/news/taiwan-approves-nt-100-million-gene-therapy-for-rare-aadc-deficiency-amid-coverage-debate 2025-12-04T05:49:36+00:00 hourly 0.9 https://trial.medpath.com/news/belite-bio-s-tinlarebant-achieves-35-7-reduction-in-lesion-growth-in-first-successful-phase-3-trial-for-stargardt-disease 2025-12-04T05:44:20+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-virginia-launches-clinical-trial-for-new-covid-19-treatment-targeting-outpatients 2025-12-04T05:44:12+00:00 hourly 0.9 https://trial.medpath.com/news/australia-issues-new-safety-warnings-for-glp-1-drugs-following-reports-of-suicidal-thoughts 2025-12-04T05:44:04+00:00 hourly 0.9 https://trial.medpath.com/news/bausch-lomb-partners-with-ripple-therapeutics-to-develop-polymer-free-sustained-release-ophthalmic-implants 2025-12-04T05:43:48+00:00 hourly 0.9 https://trial.medpath.com/news/jasper-therapeutics-reports-positive-phase-1b-data-for-briquilimab-in-asthma-completes-beacon-study-investigation 2025-12-04T05:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/roche-receives-fda-clearance-for-15-minute-point-of-care-bordetella-pcr-test 2025-12-04T05:42:54+00:00 hourly 0.9 https://trial.medpath.com/news/two-companies-launch-competing-glp-1-clinical-trials-for-feline-weight-management 2025-12-04T05:41:37+00:00 hourly 0.9 https://trial.medpath.com/news/akiram-therapeutics-advances-cd44v6-targeted-radiotherapy-akir001-with-cohort-2b-clearance-and-journal-publication 2025-12-04T05:40:58+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-alert-after-seven-deaths-linked-to-abbott-freestyle-libre-3-glucose-monitor-defects 2025-12-04T05:39:46+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-pricing-agreements-open-market-for-new-obesity-drug-competitors 2025-12-04T05:37:56+00:00 hourly 0.9 https://trial.medpath.com/news/lotus-pharma-submits-first-regulatory-application-for-vizz-presbyopia-treatment-in-south-korea 2025-12-04T05:37:54+00:00 hourly 0.9 https://trial.medpath.com/news/4d-path-s-ai-platform-predicts-chemotherapy-response-in-triple-negative-breast-cancer-using-standard-biopsy-images 2025-12-04T05:37:51+00:00 hourly 0.9 https://trial.medpath.com/news/outlook-therapeutics-awaits-critical-fda-decision-on-first-ophthalmic-bevacizumab-for-wet-amd-by-december-31 2025-12-04T05:37:15+00:00 hourly 0.9 https://trial.medpath.com/news/automated-lung-organoid-production-breakthrough-promises-to-accelerate-respiratory-drug-development 2025-12-04T05:37:13+00:00 hourly 0.9 https://trial.medpath.com/news/pentixapharm-receives-fda-guidance-for-phase-3-panda-study-of-68ga-pentixafor-in-primary-aldosteronism 2025-12-04T05:37:10+00:00 hourly 0.9 https://trial.medpath.com/news/excelsior-sciences-secures-95-million-to-revolutionize-ai-driven-small-molecule-drug-discovery 2025-12-04T05:37:07+00:00 hourly 0.9 https://trial.medpath.com/news/quadriga-biosciences-reports-promising-phase-iia-results-for-qbs72s-in-breast-cancer-leptomeningeal-disease 2025-12-04T05:37:01+00:00 hourly 0.9 https://trial.medpath.com/news/protara-s-tara-002-shows-72-complete-response-rate-in-bcg-naive-bladder-cancer-patients 2025-12-04T05:36:55+00:00 hourly 0.9 https://trial.medpath.com/news/relmada-therapeutics-presents-promising-6-month-data-for-ndv-01-bladder-cancer-treatment-at-urologic-oncology-meeting 2025-12-04T05:36:52+00:00 hourly 0.9 https://trial.medpath.com/news/illumina-and-myome-partner-to-advance-200-billion-healthcare-savings-through-ai-driven-genomic-medicine 2025-12-04T05:36:50+00:00 hourly 0.9 https://trial.medpath.com/news/who-approves-olastrocel-as-international-name-for-creative-medical-s-lead-cell-therapy-celz-201 2025-12-04T05:35:19+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-accelerated-approval-to-otsuka-s-voyxact-for-iga-nephropathy-first-april-targeting-therapy 2025-12-04T05:35:09+00:00 hourly 0.9 https://trial.medpath.com/news/cms-approves-47-payment-increase-for-optical-genome-mapping-in-blood-cancer-diagnostics 2025-12-04T05:35:07+00:00 hourly 0.9 https://trial.medpath.com/news/two-novel-alzheimer-s-therapies-advance-in-phase-2-trials-oral-pri-002-and-trem2-targeting-vhb937 2025-12-04T05:33:58+00:00 hourly 0.9 https://trial.medpath.com/news/federal-appeals-court-overturns-41-million-patent-verdict-against-daiichi-sankyo-s-enhertu-adc 2025-12-04T05:33:09+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-300mg-strength-of-celltrion-s-omlyclo-first-interchangeable-biosimilar-to-xolair 2025-12-04T05:33:03+00:00 hourly 0.9 https://trial.medpath.com/news/jaguar-health-seeks-ema-approval-for-canalevia-in-european-union-to-treat-general-diarrhea-in-dogs 2025-12-04T05:32:58+00:00 hourly 0.9 https://trial.medpath.com/news/samsung-bioepis-secures-european-approval-for-byooviz-pre-filled-syringe-formulation 2025-12-04T05:32:55+00:00 hourly 0.9 https://trial.medpath.com/news/ensysce-biosciences-secures-extended-patent-protection-for-mpar-overdose-prevention-technology-through-2042 2025-12-04T05:32:52+00:00 hourly 0.9 https://trial.medpath.com/news/strand-therapeutics-appoints-former-nimbus-ceo-jeb-keiper-to-board-as-company-advances-programmable-mrna-platform 2025-12-04T05:32:46+00:00 hourly 0.9 https://trial.medpath.com/news/china-s-pharmaceutical-patent-linkage-system-shows-growing-judicial-maturity-after-four-years-of-operation 2025-12-04T05:32:06+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-first-in-class-vectorized-antibody-trial-for-als-targeting-tdp-43-pathology 2025-12-04T05:31:51+00:00 hourly 0.9 https://trial.medpath.com/news/jupiter-neurosciences-advances-jotrol-into-phase-2a-parkinson-s-trial-following-fda-clearance 2025-12-04T05:31:48+00:00 hourly 0.9 https://trial.medpath.com/news/leqembi-shows-measurable-target-engagement-with-alzheimer-s-protofibrils-in-cerebrospinal-fluid 2025-12-04T05:31:45+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-faces-regulatory-headwinds-as-fda-signals-stricter-vaccine-approval-standards 2025-12-04T05:31:43+00:00 hourly 0.9 https://trial.medpath.com/news/nrx-pharmaceuticals-expands-nrx-101-development-to-include-combination-therapy-with-transcranial-magnetic-stimulation-for-depression 2025-12-04T05:31:40+00:00 hourly 0.9 https://trial.medpath.com/news/cosmo-s-clascoterone-5-topical-solution-achieves-breakthrough-results-in-phase-iii-male-pattern-hair-loss-trials 2025-12-04T05:31:34+00:00 hourly 0.9 https://trial.medpath.com/news/avecho-biotechnology-secures-us-and-eu-patent-protection-for-cbd-insomnia-treatment-through-2040 2025-12-04T05:31:22+00:00 hourly 0.9 https://trial.medpath.com/news/aob-pharma-secures-ema-pediatric-investigation-plan-approval-for-b244-atopic-dermatitis-treatment-with-topical-corticosteroid-waiver 2025-12-04T05:30:30+00:00 hourly 0.9 https://trial.medpath.com/news/triana-biomedicines-secures-120m-series-b-to-advance-alk-targeted-molecular-glue-degrader-for-lung-cancer 2025-12-04T05:29:53+00:00 hourly 0.9 https://trial.medpath.com/news/paradigm-trial-shows-venetoclax-azacitidine-superior-to-intensive-chemotherapy-in-newly-diagnosed-aml 2025-12-04T05:29:47+00:00 hourly 0.9 https://trial.medpath.com/news/citizen-health-and-ucb-launch-strategic-partnership-to-accelerate-epilepsy-and-rare-disease-drug-development-using-ai 2025-12-04T05:29:37+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-enfortumab-vedotin-plus-pembrolizumab-for-perioperative-treatment-of-muscle-invasive-bladder-cancer 2025-12-04T05:29:35+00:00 hourly 0.9 https://trial.medpath.com/news/greenwich-lifesciences-completes-enrollment-in-non-hla-a-02-arm-of-phase-iii-flamingo-01-trial-for-breast-cancer-prevention 2025-12-04T05:28:57+00:00 hourly 0.9 https://trial.medpath.com/news/abemaciclib-monotherapy-shows-promise-after-cdk4-6-inhibitor-failure-in-hr-her2-breast-cancer 2025-12-04T05:28:22+00:00 hourly 0.9 https://trial.medpath.com/news/alkeus-pharmaceuticals-appoints-carlos-quezada-ruiz-as-chief-medical-officer-to-lead-stargardt-disease-drug-development 2025-12-04T05:28:19+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-amneal-s-generic-cyclosporine-eye-drops-for-dry-eye-disease-treatment 2025-12-04T05:28:16+00:00 hourly 0.9 https://trial.medpath.com/news/biofrontera-submits-fda-application-for-ameluz-pdt-in-superficial-basal-cell-carcinoma-treatment 2025-12-04T05:28:11+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-daratumumab-for-high-risk-smoldering-multiple-myeloma-following-landmark-aquila-trial-results 2025-12-04T05:28:00+00:00 hourly 0.9 https://trial.medpath.com/news/zynlonta-plus-glofitamab-achieves-89-8-response-rate-in-relapsed-refractory-dlbcl-trial 2025-12-04T05:27:57+00:00 hourly 0.9 https://trial.medpath.com/news/alzecure-receives-eur2-5-million-eu-grant-to-advance-phase-2a-trial-of-novel-alzheimer-s-drug-acd856 2025-12-04T05:27:51+00:00 hourly 0.9 https://trial.medpath.com/news/harmony-biosciences-to-present-phase-3-epx-100-data-for-dravet-syndrome-at-aes-annual-meeting 2025-12-04T05:27:33+00:00 hourly 0.9 https://trial.medpath.com/news/elevar-s-rivoceranib-camrelizumab-combination-shows-significant-survival-benefit-in-phase-3-liver-cancer-trial 2025-12-04T05:27:30+00:00 hourly 0.9 https://trial.medpath.com/news/savara-secures-european-patent-protection-for-molbreevi-through-2041-strengthening-ip-portfolio-for-rare-lung-disease-therapy 2025-12-04T05:27:24+00:00 hourly 0.9 https://trial.medpath.com/news/sagent-pharmaceuticals-partners-with-provepharm-to-launch-bludigo-first-fda-approved-injectable-indigo-carmine-diagnostic-dye 2025-12-04T05:26:47+00:00 hourly 0.9 https://trial.medpath.com/news/kura-oncology-receives-135-million-milestone-payment-as-komzifti-achieves-first-commercial-sale 2025-12-04T05:26:41+00:00 hourly 0.9 https://trial.medpath.com/news/pharvaris-reports-positive-phase-3-results-for-oral-hae-treatment-deucrictibant 2025-12-04T05:26:27+00:00 hourly 0.9 https://trial.medpath.com/news/latus-bio-receives-fda-ind-clearance-for-lts-101-gene-therapy-to-treat-fatal-cln2-disease-in-children 2025-12-04T05:26:24+00:00 hourly 0.9 https://trial.medpath.com/news/immuron-secures-us-department-of-defense-award-for-novel-oral-therapeutics-against-military-priority-pathogens 2025-12-04T05:26:18+00:00 hourly 0.9 https://trial.medpath.com/news/pedmark-shows-significant-reduction-in-cisplatin-induced-hearing-loss-in-japanese-pediatric-cancer-study 2025-12-04T05:26:15+00:00 hourly 0.9 https://trial.medpath.com/news/incannex-healthcare-receives-fda-fast-track-designation-for-ihl-42x-in-obstructive-sleep-apnea 2025-12-04T05:24:25+00:00 hourly 0.9 https://trial.medpath.com/news/iolyx-therapeutics-secures-280m-partnership-with-laboratoires-thea-for-autoimmune-dry-eye-treatment 2025-12-04T05:24:22+00:00 hourly 0.9 https://trial.medpath.com/news/amneal-secures-fda-approval-for-generic-albuterol-inhaler-marking-second-respiratory-win-in-q4-2025 2025-12-04T05:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/silexion-therapeutics-receives-german-regulatory-approval-for-phase-2-3-pancreatic-cancer-trial-design 2025-12-04T05:23:57+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-presents-breakthrough-data-at-ash-2025-demonstrating-significant-advances-in-blood-cancer-treatment 2025-12-04T05:23:49+00:00 hourly 0.9 https://trial.medpath.com/news/black-diamond-therapeutics-to-present-phase-2-silevertinib-results-for-egfr-mutant-nsclc 2025-12-04T05:23:46+00:00 hourly 0.9 https://trial.medpath.com/news/delhi-high-court-allows-dr-reddy-s-to-export-semaglutide-challenges-novo-nordisk-patent-validity 2025-12-04T05:23:14+00:00 hourly 0.9 https://trial.medpath.com/news/tiakis-biotech-advances-tiprelestat-to-phase-ii-trial-for-pulmonary-arterial-hypertension-following-positive-safety-data 2025-12-04T05:23:09+00:00 hourly 0.9 https://trial.medpath.com/news/quetzal-therapeutics-initiates-phase-iii-trial-of-oral-arsenic-trioxide-qtx-2101-for-acute-promyelocytic-leukemia 2025-12-04T05:23:06+00:00 hourly 0.9 https://trial.medpath.com/news/uk-approves-tisotumab-vedotin-for-recurrent-cervical-cancer-demonstrating-30-reduction-in-death-risk 2025-12-04T05:23:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-wave-of-oncology-drugs-and-biosimilars-in-november-2025-expanding-treatment-access 2025-12-04T05:22:57+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-ziftomenib-first-in-class-targeted-therapy-for-npm1-mutated-acute-myeloid-leukemia 2025-12-04T05:22:22+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-delays-cobenfy-alzheimer-s-psychosis-trial-results-to-2026-following-site-irregularities 2025-12-04T05:21:28+00:00 hourly 0.9 https://trial.medpath.com/news/vandria-s-vna-318-shows-promising-phase-1-results-with-novel-dual-action-mechanism-for-alzheimer-s-disease 2025-12-04T05:21:22+00:00 hourly 0.9 https://trial.medpath.com/news/polaritybio-completes-phase-iii-trial-of-skinte-for-diabetic-foot-ulcers-targets-first-bla-approval-since-1997 2025-12-04T05:21:19+00:00 hourly 0.9 https://trial.medpath.com/news/ai-powered-remote-monitoring-shows-promise-for-reducing-patient-burden-in-clinical-trials 2025-12-04T05:21:16+00:00 hourly 0.9 https://trial.medpath.com/news/roche-s-trontinemab-shows-92-amyloid-clearance-success-in-alzheimer-s-mid-stage-trial 2025-12-04T05:21:14+00:00 hourly 0.9 https://trial.medpath.com/news/fda-chief-claims-covid-19-vaccines-linked-to-10-pediatric-deaths-sparking-expert-criticism-and-market-decline 2025-12-04T05:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/us-house-passes-bipartisan-bill-to-reauthorize-fda-s-rare-pediatric-disease-priority-review-voucher-program 2025-12-04T05:20:58+00:00 hourly 0.9 https://trial.medpath.com/news/roche-s-trontinemab-shows-92-success-rate-in-clearing-alzheimer-s-amyloid-plaques 2025-12-04T05:20:49+00:00 hourly 0.9 https://trial.medpath.com/news/fda-deploys-agentic-ai-across-agency-to-accelerate-drug-reviews-and-modernize-regulatory-workflows 2025-12-04T05:20:47+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-proposes-7-25-billion-roundup-settlement-as-trump-administration-backs-supreme-court-appeal 2025-12-03T22:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/medicus-pharma-appoints-carolyn-bonner-as-cfo-while-advancing-multiple-clinical-programs 2025-12-03T15:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/phase-i-trial-evaluates-pevonedistat-capecitabine-oxaliplatin-combination-for-advanced-gastric-cancer 2025-12-03T08:23:38+00:00 hourly 0.9 https://trial.medpath.com/news/imvax-plans-fda-discussions-for-glioblastoma-therapy-despite-missing-primary-endpoint 2025-12-03T06:27:05+00:00 hourly 0.9 https://trial.medpath.com/news/ai-driven-study-identifies-z-endoxifen-as-promising-therapeutic-candidate-for-glioblastoma 2025-12-03T06:25:49+00:00 hourly 0.9 https://trial.medpath.com/news/curi-bio-raises-10m-series-b-to-scale-human-ipsc-platforms-for-drug-discovery 2025-12-03T06:25:43+00:00 hourly 0.9 https://trial.medpath.com/news/diagnostear-partners-with-alyatec-for-clinical-validation-of-revolutionary-red-eye-diagnostic-test 2025-12-03T06:25:32+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-secures-fda-approval-for-imdelltra-in-small-cell-lung-cancer-as-pipeline-advances-drive-growth 2025-12-03T06:25:15+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-birchbiomed-s-fs2-for-idiopathic-pulmonary-fibrosis-treatment 2025-12-03T06:25:12+00:00 hourly 0.9 https://trial.medpath.com/news/engene-s-detalimogene-selected-for-fda-manufacturing-pilot-program-to-accelerate-bladder-cancer-gene-therapy-development 2025-12-03T06:25:06+00:00 hourly 0.9 https://trial.medpath.com/news/uk-secures-zero-tariff-us-pharmaceutical-deal-with-25-increase-in-nhs-medicine-investment 2025-12-03T06:25:01+00:00 hourly 0.9 https://trial.medpath.com/news/electra-therapeutics-advances-ela026-in-pivotal-trial-for-rare-blood-disorder-shlh 2025-12-03T06:24:49+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-draft-guidance-to-reduce-primate-testing-for-monoclonal-antibody-therapies 2025-12-03T06:24:44+00:00 hourly 0.9 https://trial.medpath.com/news/antengene-receives-nmpa-approval-for-phase-ib-ii-study-of-atg-022-cldn18-2-adc-in-combination-with-pembrolizumab-for-gastric-cancer 2025-12-03T06:23:57+00:00 hourly 0.9 https://trial.medpath.com/news/ajovy-becomes-first-cgrp-antagonist-approved-for-pediatric-migraine-prevention-following-positive-space-trial-results 2025-12-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/tang-capital-management-invests-56-8-million-in-celcuity-following-positive-phase-3-gedatolisib-results 2025-12-02T22:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/mirum-pharmaceuticals-initiates-phase-ii-trial-of-mrm-3379-for-fragile-x-syndrome 2025-12-02T15:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/breast-cancer-index-test-shows-promise-for-identifying-low-risk-premenopausal-patients-who-may-avoid-aggressive-therapy 2025-12-02T13:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/bionexus-gene-lab-launches-vitaguard-mrd-platform-across-southeast-asia-to-challenge-3000-legacy-cancer-monitoring-systems 2025-12-02T13:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/3d-printed-corneal-implant-restores-sight-to-legally-blind-patient-in-world-first-surgery 2025-12-02T12:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/neurothera-labs-pursues-quantum-computing-acquisition-to-accelerate-cns-drug-development 2025-12-02T09:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/nice-approves-papillon-brachytherapy-for-nhs-use-in-early-stage-rectal-cancer 2025-12-02T05:26:40+00:00 hourly 0.9 https://trial.medpath.com/news/lynk-pharmaceuticals-receives-fda-ind-approval-for-brain-penetrant-tyk2-inhibitor-lnk01006-targeting-neuroinflammatory-diseases 2025-12-02T05:26:21+00:00 hourly 0.9 https://trial.medpath.com/news/three-fda-approvals-in-three-months-transform-hereditary-angioedema-treatment-landscape-in-2025 2025-12-02T03:22:01+00:00 hourly 0.9 https://trial.medpath.com/news/belite-bio-raises-350-million-to-advance-retinal-disease-therapies-toward-commercialization 2025-12-02T01:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/aptargroup-acquires-brazilian-oral-dosing-specialist-sommaplast-to-expand-pharmaceutical-packaging-capabilities 2025-12-01T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/combination-immunotherapy-shows-promise-for-hiv-control-after-art-discontinuation 2025-12-01T21:31:27+00:00 hourly 0.9 https://trial.medpath.com/news/apimeds-pharmaceuticals-merges-with-ai-driven-digital-asset-company-mindwave-in-100m-deal 2025-12-01T21:27:01+00:00 hourly 0.9 https://trial.medpath.com/news/eib-and-angelini-ventures-launch-eur150-million-european-biotech-investment-initiative 2025-12-01T21:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/juniper-biosciences-secures-40-million-seed-funding-to-advance-radiopharmaceutical-pipeline 2025-12-01T17:39:59+00:00 hourly 0.9 https://trial.medpath.com/news/faron-pharmaceuticals-appoints-former-astrazeneca-executive-as-cfo-ahead-of-bexmarilimab-registrational-study 2025-12-01T17:35:49+00:00 hourly 0.9 https://trial.medpath.com/news/kiora-pharmaceuticals-secures-new-patent-for-kio-104-formulations-extending-market-protection-to-2043 2025-12-01T17:31:54+00:00 hourly 0.9 https://trial.medpath.com/news/salarius-pharmaceuticals-partners-with-texas-biomed-to-test-ai-designed-antiviral-against-h5n1-avian-flu 2025-12-01T17:31:23+00:00 hourly 0.9 https://trial.medpath.com/news/recursion-to-present-updated-clinical-data-from-phase-1b-2-trial-of-rec-4881-in-familial-adenomatous-polyposis 2025-12-01T17:31:01+00:00 hourly 0.9 https://trial.medpath.com/news/promis-neurosciences-validates-plasma-ptau-as-early-predictor-for-alzheimer-s-drug-development 2025-12-01T17:30:15+00:00 hourly 0.9 https://trial.medpath.com/news/neonc-s-neo100-shows-enhanced-brain-tumor-efficacy-when-combined-with-ultrasound-in-ai-driven-study 2025-12-01T17:30:12+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-partners-with-tessera-in-275m-gene-editing-deal-for-alpha-1-antitrypsin-deficiency-treatment 2025-12-01T17:29:31+00:00 hourly 0.9 https://trial.medpath.com/news/akebia-therapeutics-establishes-rare-kidney-disease-pipeline-with-two-novel-therapeutic-candidates 2025-12-01T17:29:29+00:00 hourly 0.9 https://trial.medpath.com/news/morphocell-technologies-completes-50-million-series-a-to-advance-liver-disease-therapeutics 2025-12-01T17:28:10+00:00 hourly 0.9 https://trial.medpath.com/news/keynote-811-trial-shows-pembrolizumab-combination-improves-response-rates-in-her2-positive-gastric-cancer 2025-12-01T17:27:34+00:00 hourly 0.9 https://trial.medpath.com/news/oncoprecision-s-first-in-class-cd64-targeting-adc-onc001-selected-for-oral-presentation-at-ash-2025 2025-12-01T17:26:45+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-presents-long-term-data-supporting-belantamab-mafodotin-and-momelotinib-for-blood-cancers-at-ash-2024 2025-12-01T17:25:58+00:00 hourly 0.9 https://trial.medpath.com/news/mabwell-s-anti-st2-antibody-9mw1911-shows-over-40-reduction-in-severe-copd-exacerbations-in-phase-iia-trial 2025-12-01T17:25:21+00:00 hourly 0.9 https://trial.medpath.com/news/saga-diagnostics-presents-breakthrough-mrd-data-at-sabcs-2025-demonstrating-100-sensitivity-in-breast-cancer-detection 2025-12-01T17:24:37+00:00 hourly 0.9 https://trial.medpath.com/news/solid-biosciences-secures-fda-rare-pediatric-disease-designation-for-novel-friedreich-s-ataxia-gene-therapy 2025-12-01T17:24:34+00:00 hourly 0.9 https://trial.medpath.com/news/merck-receives-fda-fast-track-designation-for-novel-alzheimer-s-tau-targeting-antibody-mk-2214 2025-12-01T17:23:33+00:00 hourly 0.9 https://trial.medpath.com/news/who-approves-tazbentetol-as-international-name-for-spinogenix-s-first-in-class-synaptic-regenerative-therapy 2025-12-01T17:21:51+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-isopsa-blood-test-to-reduce-unnecessary-prostate-biopsies 2025-12-01T17:21:48+00:00 hourly 0.9 https://trial.medpath.com/news/jacobio-s-kras-g12c-combination-therapy-achieves-71-response-rate-in-first-line-nsclc-trial 2025-12-01T17:21:29+00:00 hourly 0.9 https://trial.medpath.com/news/lenz-therapeutics-and-lotus-pharmaceutical-submit-vizz-for-presbyopia-treatment-approval-in-south-korea 2025-12-01T17:21:01+00:00 hourly 0.9 https://trial.medpath.com/news/lilly-launches-five-year-real-world-trial-of-tirzepatide-in-uk-primary-care-settings 2025-12-01T17:20:46+00:00 hourly 0.9 https://trial.medpath.com/news/glial-cell-immune-networks-drive-neuroinflammation-in-glaucomatous-optic-nerve-degeneration 2025-12-01T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bridgebio-pharma-advances-three-potential-first-in-class-therapies-for-rare-diseases 2025-12-01T15:51:00+00:00 hourly 0.9 https://trial.medpath.com/news/nyxoah-secures-major-cms-reimbursement-increase-for-genio-sleep-apnea-device 2025-12-01T14:14:00+00:00 hourly 0.9 https://trial.medpath.com/news/mendus-achieves-large-scale-gmp-manufacturing-milestone-for-vididencel-cell-therapy-in-aml-and-cml 2025-12-01T13:37:10+00:00 hourly 0.9 https://trial.medpath.com/news/protego-biopharma-raises-130m-to-advance-novel-protein-stabilization-approach-for-al-amyloidosis 2025-12-01T13:36:25+00:00 hourly 0.9 https://trial.medpath.com/news/compass-therapeutics-advances-oncology-pipeline-with-pivotal-tovecimig-data-expected-q1-2026 2025-12-01T13:35:42+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-s-atogepant-shows-superior-efficacy-in-phase-3-eclipse-trial-for-acute-migraine-treatment 2025-12-01T13:35:37+00:00 hourly 0.9 https://trial.medpath.com/news/ideaya-biosciences-receives-fda-clearance-for-first-in-class-bispecific-adc-ide034-targeting-multiple-solid-tumors 2025-12-01T13:24:06+00:00 hourly 0.9 https://trial.medpath.com/news/wockhardt-shares-surge-19-following-fda-acceptance-of-zaynich-antibiotic-application 2025-12-01T13:23:29+00:00 hourly 0.9 https://trial.medpath.com/news/zentiva-launches-first-biosimilar-monoclonal-antibody-across-eu-markets 2025-12-01T13:23:06+00:00 hourly 0.9 https://trial.medpath.com/news/injectable-hiv-treatment-shows-promise-in-african-trial-offering-hope-for-improved-adherence 2025-12-01T09:25:55+00:00 hourly 0.9 https://trial.medpath.com/news/enlivex-therapeutics-secures-212-million-funding-for-osteoarthritis-therapy-development-and-digital-asset-strategy 2025-12-01T09:25:23+00:00 hourly 0.9 https://trial.medpath.com/news/theia-ventures-leads-pre-seed-funding-for-lemnisca-s-ai-driven-biomanufacturing-platform 2025-12-01T09:25:11+00:00 hourly 0.9 https://trial.medpath.com/news/menin-inhibitors-show-promise-as-targeted-therapy-for-aggressive-kmt2a-rearranged-acute-leukemia 2025-12-01T09:23:40+00:00 hourly 0.9 https://trial.medpath.com/news/australian-regulator-updates-safety-warnings-for-glp-1-drugs-over-suicidal-ideation-risk 2025-12-01T05:24:55+00:00 hourly 0.9 https://trial.medpath.com/news/nitrous-oxide-shows-promise-as-rapid-acting-treatment-for-treatment-resistant-depression 2025-12-01T05:22:23+00:00 hourly 0.9 https://trial.medpath.com/news/nevada-health-centers-partners-with-javara-to-expand-clinical-trial-access-including-norovirus-vaccine-study 2025-12-01T05:22:18+00:00 hourly 0.9 https://trial.medpath.com/news/zuellig-pharma-opens-advanced-clinical-trial-support-innovation-center-in-south-korea 2025-12-01T05:22:15+00:00 hourly 0.9 https://trial.medpath.com/news/nanoviricides-submits-orphan-drug-application-for-nv-387-measles-treatment-as-cases-surge-in-us 2025-12-01T02:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-trial-data-managers-lose-12-hours-weekly-to-manual-tasks-raising-quality-concerns 2025-12-01T01:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/scisparc-acquires-muse-endoscopy-patent-portfolio-to-enter-2-5-billion-gerd-device-market 2025-12-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/avandra-health-acquires-datcard-systems-and-sorna-corporation-to-create-world-s-largest-medical-imaging-platform 2025-11-30T17:23:40+00:00 hourly 0.9 https://trial.medpath.com/news/gut-brain-axis-emerges-as-key-pathway-in-parkinson-s-disease-pathogenesis 2025-11-30T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cereno-scientific-secures-sek-665-million-financing-to-advance-rare-disease-pipeline-through-2027 2025-11-30T13:22:14+00:00 hourly 0.9 https://trial.medpath.com/news/nigeria-s-niprd-and-futh-lafia-partner-to-advance-local-vaccine-and-drug-development 2025-11-30T05:21:44+00:00 hourly 0.9 https://trial.medpath.com/news/ace2-decoy-receptor-shows-promise-against-multiple-sars-cov-2-variants-in-new-study 2025-11-29T21:24:09+00:00 hourly 0.9 https://trial.medpath.com/news/single-2-ml-mirikizumab-injection-demonstrates-bioequivalence-to-two-1-ml-doses-in-healthy-participants 2025-11-29T21:22:05+00:00 hourly 0.9 https://trial.medpath.com/news/ultrasound-activated-nanocatalysts-trigger-novel-cancer-cell-death-mechanism-in-preclinical-study 2025-11-29T21:21:59+00:00 hourly 0.9 https://trial.medpath.com/news/fda-internal-memo-links-10-pediatric-deaths-to-covid-19-vaccination-citing-myocarditis-concerns 2025-11-29T14:25:05+00:00 hourly 0.9 https://trial.medpath.com/news/zura-bio-advances-tibulizumab-phase-2-trials-with-139-million-cash-runway-through-2027 2025-11-29T14:24:04+00:00 hourly 0.9 https://trial.medpath.com/news/novel-hdac2-inhibitor-shows-promise-for-cancer-therapy-despite-acute-toxicity-concerns 2025-11-29T09:23:13+00:00 hourly 0.9 https://trial.medpath.com/news/dea-finalizes-significant-increases-in-psychedelic-production-quotas-for-2026-to-support-ptsd-and-depression-research 2025-11-29T01:24:51+00:00 hourly 0.9 https://trial.medpath.com/news/terumo-bct-partners-with-santersus-to-advance-novel-blood-purification-technology-for-sepsis-treatment 2025-11-29T01:23:30+00:00 hourly 0.9 https://trial.medpath.com/news/australian-researchers-identify-romidepsin-as-breakthrough-treatment-for-relapsed-neuroblastoma 2025-11-29T01:22:55+00:00 hourly 0.9 https://trial.medpath.com/news/hanmi-pharmaceutical-s-hm16390-shows-dual-mechanism-for-enhanced-cancer-immunotherapy-safety-and-efficacy 2025-11-28T21:24:13+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-meta-analysis-confirms-galcanezumab-efficacy-in-migraine-prevention-across-3859-patients 2025-11-28T21:22:31+00:00 hourly 0.9 https://trial.medpath.com/news/pasithea-therapeutics-secures-60-million-funding-to-advance-mek-inhibitor-for-neurofibromatosis-treatment 2025-11-28T17:30:20+00:00 hourly 0.9 https://trial.medpath.com/news/canada-s-drug-agency-recommends-public-reimbursement-for-skyrizi-in-ulcerative-colitis 2025-11-28T17:25:56+00:00 hourly 0.9 https://trial.medpath.com/news/novel-biopolymeric-nanocarrier-system-targets-cd44-receptors-for-enhanced-irinotecan-delivery-in-skin-cancer-treatment 2025-11-28T17:25:39+00:00 hourly 0.9 https://trial.medpath.com/news/veraxa-biotech-s-nasdaq-listing-back-on-track-after-us-government-shutdown-delays 2025-11-28T17:25:22+00:00 hourly 0.9 https://trial.medpath.com/news/ge-healthcare-receives-ce-mark-for-revolutionary-total-body-pet-ct-system-and-digital-spect-ct-platform 2025-11-28T17:24:41+00:00 hourly 0.9 https://trial.medpath.com/news/cytiva-and-veeda-lifesciences-establish-host-cell-protein-analysis-center-in-india-to-support-biopharmaceutical-development 2025-11-28T17:23:45+00:00 hourly 0.9 https://trial.medpath.com/news/china-s-first-dual-indication-car-t-therapy-receives-nmpa-approval-for-large-b-cell-lymphoma 2025-11-28T17:23:07+00:00 hourly 0.9 https://trial.medpath.com/news/profound-medical-launches-ai-powered-bph-module-and-expands-global-reach-through-strategic-partnerships 2025-11-28T17:22:58+00:00 hourly 0.9 https://trial.medpath.com/news/ephb4-targeted-car-t-cell-therapy-enters-phase-i-trial-for-solid-tumors 2025-11-28T13:27:27+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-engineer-mrna-modified-allogeneic-mscs-for-enhanced-t-cell-immunotherapy 2025-11-28T13:25:43+00:00 hourly 0.9 https://trial.medpath.com/news/lmu-researchers-develop-ai-powered-platform-to-accelerate-rna-drug-carrier-design 2025-11-28T13:25:40+00:00 hourly 0.9 https://trial.medpath.com/news/gene-solutions-launches-ai-powered-spot-mas-multi-cancer-screening-platform-in-taiwan 2025-11-28T13:23:00+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-first-domestic-il-23p19-antibody-for-psoriasis-treatment 2025-11-28T13:22:58+00:00 hourly 0.9 https://trial.medpath.com/news/innocare-initiates-global-phase-ii-trial-of-tyk2-inhibitor-soficitinib-for-prurigo-nodularis-treatment 2025-11-28T09:22:56+00:00 hourly 0.9 https://trial.medpath.com/news/pre-transplant-treg-expansion-therapy-shows-promise-for-reducing-gvhd-risk-in-blood-cancer-patients 2025-11-28T09:21:03+00:00 hourly 0.9 https://trial.medpath.com/news/fzocus-1-trial-shows-fuzuloparib-maintenance-therapy-improves-survival-in-advanced-ovarian-cancer 2025-11-28T01:24:17+00:00 hourly 0.9 https://trial.medpath.com/news/bone-metastasis-treatment-pipeline-shows-robust-development-with-10-companies-advancing-novel-therapies 2025-11-28T01:23:55+00:00 hourly 0.9 https://trial.medpath.com/news/ge-healthcare-receives-fda-authorization-for-ai-powered-3d-mammography-technology 2025-11-28T01:23:41+00:00 hourly 0.9 https://trial.medpath.com/news/northwestern-researchers-develop-reengineered-hpv-vaccine-that-trains-t-cells-to-hunt-cancer 2025-11-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/transgene-secures-eur105-million-to-advance-personalized-cancer-vaccine-platform 2025-11-27T21:24:18+00:00 hourly 0.9 https://trial.medpath.com/news/stanford-researchers-demonstrate-cartilage-regeneration-through-gerozyme-inhibition-in-preclinical-studies 2025-11-27T21:22:08+00:00 hourly 0.9 https://trial.medpath.com/news/mbx-biosciences-advances-toward-phase-3-trial-despite-major-investor-exit 2025-11-27T20:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/maibe-and-leniobio-form-strategic-partnership-to-accelerate-ai-driven-monoclonal-antibody-discovery 2025-11-27T17:24:21+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-s-mrna-norovirus-vaccine-enters-phase-3-trial-at-newcastle-hospitals 2025-11-27T17:24:13+00:00 hourly 0.9 https://trial.medpath.com/news/neuraxpharm-and-mjn-neuro-launch-ai-powered-wearable-device-for-early-epileptic-seizure-detection 2025-11-27T17:20:52+00:00 hourly 0.9 https://trial.medpath.com/news/efgartigimod-shows-promise-in-treating-immune-checkpoint-inhibitor-associated-myocarditis-and-myasthenia-gravis 2025-11-27T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/monthly-tezepelumab-injection-enables-severe-asthma-patients-to-discontinue-daily-steroids 2025-11-27T13:26:20+00:00 hourly 0.9 https://trial.medpath.com/news/mendus-reports-positive-2-year-follow-up-data-for-vididencel-immunotherapy-in-high-risk-ovarian-cancer 2025-11-27T13:26:07+00:00 hourly 0.9 https://trial.medpath.com/news/patronus-biotech-secures-gates-foundation-grant-for-novel-multi-stage-malaria-vaccine-development 2025-11-27T13:25:32+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-medivir-s-miv-711-orphan-drug-designation-for-osteogenesis-imperfecta-treatment 2025-11-27T13:24:58+00:00 hourly 0.9 https://trial.medpath.com/news/gan-lee-pharmaceuticals-launches-phase-3-trial-for-once-monthly-glp-1-receptor-agonist-bofanglutide 2025-11-27T13:24:52+00:00 hourly 0.9 https://trial.medpath.com/news/ema-grants-orphan-drug-designation-to-kedrion-s-ceruloplasmin-treatment-for-rare-iron-metabolism-disorder 2025-11-27T13:23:14+00:00 hourly 0.9 https://trial.medpath.com/news/fda-withdraws-asbestos-testing-rule-for-talc-cosmetics-plans-revised-proposal 2025-11-27T13:23:06+00:00 hourly 0.9 https://trial.medpath.com/news/delphx-capital-markets-completes-c-112000-private-placement-to-support-structured-products-development 2025-11-27T13:14:00+00:00 hourly 0.9 https://trial.medpath.com/news/sk-biopharmaceuticals-licenses-wt-7695-radiopharmaceutical-targeting-ca9-for-solid-tumors 2025-11-27T10:23:48+00:00 hourly 0.9 https://trial.medpath.com/news/fda-backed-anti-aging-drug-for-dogs-targets-2026-launch-following-efficacy-approval 2025-11-27T08:24:22+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-developed-her2-targeting-adc-tqb2102-achieves-77-complete-response-rate-in-phase-ii-breast-cancer-trial 2025-11-27T08:23:13+00:00 hourly 0.9 https://trial.medpath.com/news/mhra-approves-inavolisib-for-advanced-hr-positive-her2-negative-breast-cancer 2025-11-27T05:21:43+00:00 hourly 0.9 https://trial.medpath.com/news/federal-r-d-budget-cuts-threaten-us-biomedical-innovation-leadership 2025-11-27T03:21:20+00:00 hourly 0.9 https://trial.medpath.com/news/heartbeam-pursues-multiple-regulatory-paths-after-fda-rejects-12-lead-ecg-synthesis-software-application 2025-11-27T01:29:04+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-zotiraciclib-for-idh-mutant-recurrent-high-grade-glioma 2025-11-27T01:29:02+00:00 hourly 0.9 https://trial.medpath.com/news/imugene-partners-with-jw-therapeutics-to-develop-first-in-class-car-t-combination-for-solid-tumors 2025-11-27T01:27:37+00:00 hourly 0.9 https://trial.medpath.com/news/arrowhead-pharmaceuticals-soars-23-on-fda-approval-of-redemplo-for-rare-genetic-disease 2025-11-27T01:26:19+00:00 hourly 0.9 https://trial.medpath.com/news/zetagen-therapeutics-raises-12-9m-in-oversubscribed-series-b1-round-following-promising-phase-2a-results-for-breast-cancer-treatment 2025-11-27T01:25:34+00:00 hourly 0.9 https://trial.medpath.com/news/kinase-inhibitors-discovered-to-trigger-widespread-protein-degradation-beyond-traditional-inhibition 2025-11-27T01:25:32+00:00 hourly 0.9 https://trial.medpath.com/news/engasertib-shows-promise-in-first-controlled-trial-for-hereditary-hemorrhagic-telangiectasia 2025-11-27T01:24:07+00:00 hourly 0.9 https://trial.medpath.com/news/valneva-consolidates-french-operations-closes-nantes-facility-amid-regulatory-setbacks 2025-11-26T21:28:12+00:00 hourly 0.9 https://trial.medpath.com/news/missing-prkci-gene-enhances-immunotherapy-response-in-lung-adenocarcinoma-through-senescent-cell-activation 2025-11-26T21:25:48+00:00 hourly 0.9 https://trial.medpath.com/news/piramal-pharma-solutions-achieves-full-regulatory-compliance-for-nitrosamine-impurities 2025-11-26T21:24:03+00:00 hourly 0.9 https://trial.medpath.com/news/arrowhead-pharmaceuticals-achieves-fda-approval-for-rodemplo-reports-strong-financial-turnaround 2025-11-26T21:22:55+00:00 hourly 0.9 https://trial.medpath.com/news/enveric-biosciences-secures-fourth-patent-for-non-hallucinogenic-neuroplastogenic-drug-candidates 2025-11-26T17:28:45+00:00 hourly 0.9 https://trial.medpath.com/news/mount-sinai-researchers-develop-novel-mrna-therapy-to-combat-antibiotic-resistant-bacterial-infections 2025-11-26T17:26:16+00:00 hourly 0.9 https://trial.medpath.com/news/scisparc-acquires-musetm-endoscopy-patents-to-target-3-billion-gerd-device-market 2025-11-26T17:25:47+00:00 hourly 0.9 https://trial.medpath.com/news/xoma-royalty-completes-2-035-per-share-acquisition-of-mural-oncology 2025-11-26T17:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/tangram-therapeutics-advances-novel-rnai-therapy-tgm-312-to-clinical-trials-for-mash-treatment 2025-11-26T17:24:57+00:00 hourly 0.9 https://trial.medpath.com/news/lighthouse-pharmaceuticals-secures-49-2m-nih-grant-for-novel-alzheimer-s-treatment-targeting-bacterial-driver 2025-11-26T17:24:51+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-novartis-gene-therapy-itvisma-for-spinal-muscular-atrophy-in-older-patients 2025-11-26T17:23:32+00:00 hourly 0.9 https://trial.medpath.com/news/clairity-myriad-genetics-and-magview-launch-first-integrated-ai-genetic-risk-platform-for-breast-cancer-screening 2025-11-26T17:20:45+00:00 hourly 0.9 https://trial.medpath.com/news/four-gene-signature-predicts-oxaliplatin-response-in-colorectal-cancer 2025-11-26T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-atopic-dermatitis-patients-often-excluded-from-clinical-trials-study-reveals-safety-differences 2025-11-26T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/zymfentra-shows-consistent-efficacy-across-crohn-s-disease-locations-in-post-hoc-analysis-of-liberty-cd-study 2025-11-26T13:23:03+00:00 hourly 0.9 https://trial.medpath.com/news/fda-launches-public-input-process-for-bsufa-iv-reauthorization-to-shape-biosimilar-regulatory-framework-through-2032 2025-11-26T09:22:44+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-updated-label-for-unloxcyt-based-on-long-term-data-showing-improved-outcomes-in-advanced-cutaneous-squamous-cell-carcinoma 2025-11-26T09:21:41+00:00 hourly 0.9 https://trial.medpath.com/news/samsung-biologics-reaches-400-global-manufacturing-approvals-reinforcing-cdmo-leadership 2025-11-26T09:21:39+00:00 hourly 0.9 https://trial.medpath.com/news/glenmark-launches-world-s-first-nebulized-triple-therapy-for-copd-treatment 2025-11-26T09:21:03+00:00 hourly 0.9 https://trial.medpath.com/news/galux-secures-29-million-series-b-to-advance-ai-driven-protein-design-platform 2025-11-26T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/abbott-initiates-voluntary-correction-for-3-million-freestyle-libre-3-glucose-sensors-following-false-low-reading-reports 2025-11-26T05:24:04+00:00 hourly 0.9 https://trial.medpath.com/news/long-acting-donepezil-depot-injection-shows-promise-for-canine-cognitive-dysfunction-treatment 2025-11-26T05:22:55+00:00 hourly 0.9 https://trial.medpath.com/news/chugai-pharmaceutical-and-biomy-partner-to-develop-ai-powered-cancer-pathology-diagnostic-support-programs 2025-11-26T05:22:38+00:00 hourly 0.9 https://trial.medpath.com/news/fda-extends-review-timeline-for-ascendis-pharma-s-achondroplasia-treatment-to-february-2026 2025-11-26T01:26:25+00:00 hourly 0.9 https://trial.medpath.com/news/chugai-s-port-delivery-system-with-ranibizumab-shows-promise-in-japanese-phase-i-ii-trial-for-retinal-diseases 2025-11-26T01:23:38+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-reformulated-ranitidine-after-five-year-market-absence-due-to-carcinogen-concerns 2025-11-26T01:23:28+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-first-accelerated-approval-for-novel-iga-nephropathy-treatment-voyxact 2025-11-26T01:22:23+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-reveals-higher-than-expected-atrial-fibrillation-risk-with-mavacamten-in-hypertrophic-cardiomyopathy-patients 2025-11-26T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-intravaginal-mrna-platform-delivers-enhanced-hiv-protection-through-localized-antibody-production 2025-11-25T21:30:17+00:00 hourly 0.9 https://trial.medpath.com/news/canada-s-1-5-billion-rare-disease-strategy-shows-early-success-with-nine-life-saving-treatments 2025-11-25T21:27:37+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-restructures-swiss-operations-with-550-job-cuts-while-investing-80m-in-rna-therapy-production 2025-11-25T21:27:16+00:00 hourly 0.9 https://trial.medpath.com/news/gilead-acquires-sprint-bioscience-s-trex1-cancer-program-in-414-million-deal 2025-11-25T21:24:32+00:00 hourly 0.9 https://trial.medpath.com/news/lixte-biotechnology-acquires-liora-technologies-light-proton-therapy-system-for-cancer-treatment 2025-11-25T21:24:27+00:00 hourly 0.9 https://trial.medpath.com/news/apatinib-plus-chemotherapy-extends-progression-free-survival-in-advanced-osteosarcoma-phase-ii-trial 2025-11-25T21:24:15+00:00 hourly 0.9 https://trial.medpath.com/news/ceribell-receives-fda-clearance-for-ai-powered-seizure-detection-in-neonates 2025-11-25T21:23:14+00:00 hourly 0.9 https://trial.medpath.com/news/zanidatamab-demonstrates-durable-responses-in-her2-positive-biliary-tract-cancer-earns-fda-accelerated-approval 2025-11-25T21:23:07+00:00 hourly 0.9 https://trial.medpath.com/news/new-market-analysis-reveals-global-monkeypox-clinical-trial-landscape-and-strategic-investment-opportunities 2025-11-25T21:21:13+00:00 hourly 0.9 https://trial.medpath.com/news/xenon-pharmaceuticals-to-present-long-term-azetukalner-data-at-aes-2025-highlighting-extended-seizure-freedom 2025-11-25T17:32:46+00:00 hourly 0.9 https://trial.medpath.com/news/sarepta-receives-fda-approval-for-enhanced-elevidys-gene-therapy-trial-in-non-ambulatory-duchenne-patients 2025-11-25T17:29:56+00:00 hourly 0.9 https://trial.medpath.com/news/adalyon-appoints-former-novo-nordisk-director-as-ceo-to-advance-ai-powered-speech-biomarkers-for-clinical-trials 2025-11-25T17:29:10+00:00 hourly 0.9 https://trial.medpath.com/news/innova-therapeutics-acquires-enci-therapeutics-to-advance-first-in-class-sfrp2-targeting-cancer-antibody 2025-11-25T17:28:28+00:00 hourly 0.9 https://trial.medpath.com/news/who-approves-international-name-for-os-therapies-osteosarcoma-immunotherapy-ahead-of-regulatory-submissions 2025-11-25T17:28:10+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-s-amycretin-shows-promising-phase-2-results-in-type-2-diabetes-advances-to-phase-3-trials 2025-11-25T17:26:46+00:00 hourly 0.9 https://trial.medpath.com/news/caring-cross-partners-with-amrita-research-center-to-develop-affordable-car-t-and-gene-therapies-for-underserved-indian-populations 2025-11-25T17:26:29+00:00 hourly 0.9 https://trial.medpath.com/news/tyrosine-kinase-inhibitors-and-gene-therapies-show-promise-for-wet-amd-treatment 2025-11-25T17:26:13+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expands-max-3tm-syringeless-mri-injector-for-use-with-vueway-r-imaging-bulk-package 2025-11-25T17:24:05+00:00 hourly 0.9 https://trial.medpath.com/news/precisionlife-and-ovation-partner-to-develop-precision-medicine-test-for-glp-1-drug-reimbursement 2025-11-25T17:23:45+00:00 hourly 0.9 https://trial.medpath.com/news/kelun-s-trop2-targeted-adc-shows-promise-in-first-line-lung-cancer-trial 2025-11-25T17:23:03+00:00 hourly 0.9 https://trial.medpath.com/news/pasithea-therapeutics-receives-1-million-als-association-grant-to-advance-pas-004-mek-inhibitor-in-phase-1-als-trial 2025-11-25T13:26:26+00:00 hourly 0.9 https://trial.medpath.com/news/nice-recommends-aucatzyl-car-t-therapy-for-adult-relapsed-refractory-b-cell-all-in-england-and-wales 2025-11-25T13:25:42+00:00 hourly 0.9 https://trial.medpath.com/news/active-biotech-secures-us-patent-for-tasquinimod-formulation-extending-market-exclusivity-to-2042 2025-11-25T13:24:34+00:00 hourly 0.9 https://trial.medpath.com/news/biomed-x-and-abbvie-launch-neuroscience-collaboration-to-target-anhedonia-mechanisms 2025-11-25T09:33:19+00:00 hourly 0.9 https://trial.medpath.com/news/ai-powered-launch-intelligence-transforms-pharmaceutical-market-entry-strategy 2025-11-25T07:47:31+00:00 hourly 0.9 https://trial.medpath.com/news/european-commission-approves-dupixent-as-first-line-targeted-therapy-for-chronic-spontaneous-urticaria 2025-11-25T06:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/ascentage-pharma-s-olverembatinib-shows-23-1-response-rate-in-rare-gist-subtype-with-novel-lipid-metabolism-mechanism 2025-11-25T05:26:22+00:00 hourly 0.9 https://trial.medpath.com/news/verrica-pharmaceuticals-secures-50-million-financing-to-advance-dermatology-pipeline-and-eliminate-debt 2025-11-25T05:26:03+00:00 hourly 0.9 https://trial.medpath.com/news/otsuka-submits-fda-application-for-first-in-class-adhd-drug-centanafadine 2025-11-25T05:22:50+00:00 hourly 0.9 https://trial.medpath.com/news/nhs-approves-breakthrough-car-t-therapy-obe-cel-for-aggressive-leukemia-with-77-remission-rate 2025-11-25T05:22:15+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-discontinuation-before-pregnancy-linked-to-increased-weight-gain-and-complications 2025-11-25T01:28:54+00:00 hourly 0.9 https://trial.medpath.com/news/overweight-multiple-myeloma-patients-show-worse-outcomes-with-anti-bcma-car-t-therapy-in-u-shaped-bmi-pattern 2025-11-25T01:27:33+00:00 hourly 0.9 https://trial.medpath.com/news/calcium-activated-switch-enhances-antibody-drug-conjugate-delivery-and-potency-in-cancer-treatment 2025-11-25T01:26:50+00:00 hourly 0.9 https://trial.medpath.com/news/praxis-precision-medicines-to-showcase-epilepsy-pipeline-at-aes-2025-with-full-radiant-study-results 2025-11-25T01:24:33+00:00 hourly 0.9 https://trial.medpath.com/news/artera-s-ai-model-shows-promise-for-personalizing-breast-cancer-treatment-decisions 2025-11-25T01:24:30+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-receives-european-commission-approval-for-breyanzi-in-relapsed-refractory-mantle-cell-lymphoma 2025-11-25T01:23:49+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-intrathecal-gene-therapy-for-spinal-muscular-atrophy-across-all-ages 2025-11-25T01:23:17+00:00 hourly 0.9 https://trial.medpath.com/news/aidoc-achieves-fda-clearance-for-healthcare-s-first-comprehensive-foundation-model-ai-triage-solution 2025-11-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/thermo-fisher-scientific-opens-advanced-therapies-collaboration-center-in-philadelphia-to-accelerate-cell-and-gene-therapy-development 2025-11-24T22:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/enquyst-technologies-achieves-breakthrough-in-monoclonal-antibody-manufacturing-with-chromatography-free-purification-platform 2025-11-24T21:26:08+00:00 hourly 0.9 https://trial.medpath.com/news/kelonia-s-in-vivo-car-t-therapy-shows-promising-early-results-in-multiple-myeloma-patients 2025-11-24T21:25:19+00:00 hourly 0.9 https://trial.medpath.com/news/ucla-receives-6-7-million-grant-to-expand-groundbreaking-kidney-transplant-trial-that-eliminates-immunosuppressive-drugs 2025-11-24T21:21:26+00:00 hourly 0.9 https://trial.medpath.com/news/adaptive-biotechnologies-clonoseq-mrd-test-featured-in-record-89-abstracts-at-ash-2025 2025-11-24T17:41:35+00:00 hourly 0.9 https://trial.medpath.com/news/day-one-reports-three-year-ojemda-data-shows-sustained-treatment-free-periods-in-pediatric-brain-cancer 2025-11-24T17:41:13+00:00 hourly 0.9 https://trial.medpath.com/news/capricor-therapeutics-advances-exosome-drug-delivery-with-scalable-manufacturing-framework 2025-11-24T17:39:28+00:00 hourly 0.9 https://trial.medpath.com/news/dana-farber-presents-breakthrough-findings-in-blood-cancer-treatment-at-ash-2025 2025-11-24T17:38:14+00:00 hourly 0.9 https://trial.medpath.com/news/menarini-group-to-present-new-elzonris-data-at-ash-2025-including-promising-triplet-therapy-results-for-bpdcn 2025-11-24T17:36:18+00:00 hourly 0.9 https://trial.medpath.com/news/harmony-biosciences-reports-positive-bioequivalence-results-for-pitolisant-gr-formulation-plans-2026-nda-submission 2025-11-24T17:35:06+00:00 hourly 0.9 https://trial.medpath.com/news/invivyd-selects-vby329-as-potential-best-in-class-rsv-antibody-for-pediatric-prevention 2025-11-24T17:34:52+00:00 hourly 0.9 https://trial.medpath.com/news/adia-nutrition-submits-patent-pending-autism-protocol-for-irb-review-advancing-stem-cell-therapy-study 2025-11-24T17:34:16+00:00 hourly 0.9 https://trial.medpath.com/news/vertero-therapeutics-launches-phase-1-trial-of-vt-5006-first-in-class-gut-selective-therapy-for-parkinson-s-disease 2025-11-24T17:31:18+00:00 hourly 0.9 https://trial.medpath.com/news/amorphical-enrolls-first-patient-in-phase-2-trial-testing-novel-nano-amorphous-mineral-therapy-for-stage-iv-pancreatic-cancer 2025-11-24T17:31:12+00:00 hourly 0.9 https://trial.medpath.com/news/thiogenesis-therapeutics-plans-phase-3-trial-for-next-generation-cystinosis-treatment-tti-0102 2025-11-24T17:28:55+00:00 hourly 0.9 https://trial.medpath.com/news/jyong-biotech-signs-letter-of-intent-for-mcs-2-licensing-in-south-korea 2025-11-24T17:28:46+00:00 hourly 0.9 https://trial.medpath.com/news/can-fite-seeks-veterinary-partnerships-for-cancer-drug-namodenoson-at-biofit-2025 2025-11-24T17:27:06+00:00 hourly 0.9 https://trial.medpath.com/news/heidelberg-pharma-appoints-dr-dongzhou-jeffery-liu-as-new-ceo-amid-leadership-transition 2025-11-24T17:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/biogen-partners-with-dayra-therapeutics-in-50-million-deal-to-develop-oral-macrocyclic-peptides-for-immunological-conditions 2025-11-24T17:26:51+00:00 hourly 0.9 https://trial.medpath.com/news/oral-semaglutide-fails-to-slow-alzheimer-s-disease-progression-in-phase-3-trials 2025-11-24T17:26:24+00:00 hourly 0.9 https://trial.medpath.com/news/in-vivo-car-t-therapies-drive-6-1-billion-in-biotech-acquisitions-as-investors-shift-from-traditional-cell-therapy-approaches 2025-11-24T17:26:13+00:00 hourly 0.9 https://trial.medpath.com/news/merck-s-cladribine-capsules-receive-fda-fast-track-designation-for-rare-neuromuscular-disorder 2025-11-24T17:26:10+00:00 hourly 0.9 https://trial.medpath.com/news/ocular-therapeutix-initiates-helios-3-phase-3-trial-for-axpaxli-in-diabetic-retinopathy 2025-11-24T17:25:29+00:00 hourly 0.9 https://trial.medpath.com/news/ropeginterferon-alfa-2b-shows-superior-efficacy-over-anagrelide-in-phase-3-essential-thrombocythemia-trial 2025-11-24T17:24:40+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-s-posdinemab-fails-phase-2b-trial-dealing-blow-to-tau-targeting-alzheimer-s-therapies 2025-11-24T17:23:44+00:00 hourly 0.9 https://trial.medpath.com/news/circular-genomics-unveils-blood-based-circular-rna-biomarkers-for-early-alzheimer-s-disease-detection 2025-11-24T17:23:35+00:00 hourly 0.9 https://trial.medpath.com/news/versant-ventures-launches-dayra-therapeutics-with-70m-funding-and-biogen-partnership-for-oral-macrocyclic-peptides 2025-11-24T17:22:27+00:00 hourly 0.9 https://trial.medpath.com/news/neurosense-receives-fda-clearance-for-pivotal-phase-3-trial-of-primec-in-als 2025-11-24T17:22:07+00:00 hourly 0.9 https://trial.medpath.com/news/tumor-associated-macrophages-drive-gastric-cancer-progression-through-immune-evasion-and-therapeutic-resistance 2025-11-24T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/century-old-diabetes-drug-metformin-reduces-insulin-requirements-in-type-1-diabetes-patients 2025-11-24T13:25:10+00:00 hourly 0.9 https://trial.medpath.com/news/mrna-technology-shows-promise-for-preventing-muscle-damage-from-snakebites 2025-11-24T13:25:02+00:00 hourly 0.9 https://trial.medpath.com/news/vaximm-secures-potential-835m-deal-with-bcm-europe-for-oral-cancer-immunotherapy-platform-vxm01 2025-11-24T13:24:59+00:00 hourly 0.9 https://trial.medpath.com/news/genenta-science-reports-sustained-survival-benefits-in-glioblastoma-trial-with-temferon-cell-therapy 2025-11-24T13:24:03+00:00 hourly 0.9 https://trial.medpath.com/news/pin-therapeutics-begins-first-in-human-trial-of-ck1a-degrader-pin-5018-for-rare-adenoid-cystic-carcinoma 2025-11-24T13:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/ananda-pharma-exits-public-markets-and-nhs-epilepsy-trial-to-focus-on-pain-treatment-pipeline 2025-11-24T13:23:37+00:00 hourly 0.9 https://trial.medpath.com/news/abbott-laboratories-to-acquire-exact-sciences-for-21-billion-in-major-cancer-diagnostics-consolidation 2025-11-24T13:23:07+00:00 hourly 0.9 https://trial.medpath.com/news/sequana-medical-achieves-first-u-s-commercial-implantation-of-alfapump-r-system-at-mount-sinai-hospital 2025-11-24T13:22:25+00:00 hourly 0.9 https://trial.medpath.com/news/fda-cleared-ai-platform-somnum-reduces-sleep-clinical-trial-timelines-by-50 2025-11-24T13:22:05+00:00 hourly 0.9 https://trial.medpath.com/news/biocortex-partners-with-cd-biopharma-to-accelerate-precision-immunotherapy-development-using-ai-driven-platform 2025-11-24T13:22:02+00:00 hourly 0.9 https://trial.medpath.com/news/dexamethasone-shows-promise-against-therapy-resistant-breast-cancer-metastases-in-preclinical-studies 2025-11-24T13:21:29+00:00 hourly 0.9 https://trial.medpath.com/news/samsung-biologics-completes-strategic-spinoff-to-enhance-biosimilar-and-novel-drug-development 2025-11-24T09:22:51+00:00 hourly 0.9 https://trial.medpath.com/news/austrian-multicenter-study-demonstrates-hifu-as-effective-organ-preserving-treatment-for-early-prostate-cancer 2025-11-24T09:22:46+00:00 hourly 0.9 https://trial.medpath.com/news/fda-regulatory-reversals-disrupt-drug-development-timelines-for-uniqure-biohaven-and-capricor 2025-11-24T09:21:32+00:00 hourly 0.9 https://trial.medpath.com/news/china-s-biotech-sector-emerges-as-key-player-as-big-pharma-faces-300-billion-patent-cliff-through-2030 2025-11-24T08:05:38+00:00 hourly 0.9 https://trial.medpath.com/news/triple-negative-breast-cancer-pipeline-expands-with-170-emerging-therapies-across-multiple-development-phases 2025-11-24T07:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/world-first-gene-therapy-shows-remarkable-success-in-three-year-old-with-hunter-syndrome 2025-11-24T05:21:49+00:00 hourly 0.9 https://trial.medpath.com/news/harbour-biomed-expands-astrazeneca-partnership-for-next-generation-oncology-therapeutics 2025-11-24T05:21:18+00:00 hourly 0.9 https://trial.medpath.com/news/geneditbio-and-toolgen-form-strategic-alliance-to-advance-crispr-based-cardiovascular-gene-therapy 2025-11-24T05:21:10+00:00 hourly 0.9 https://trial.medpath.com/news/hpv-vaccination-shows-dramatic-80-reduction-in-cervical-cancer-risk-when-given-before-age-16 2025-11-24T04:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/rakovina-therapeutics-presents-ai-discovered-cns-penetrant-atr-mtor-dual-inhibitors-at-neuro-oncology-meeting 2025-11-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-s-asundexian-shows-promise-in-phase-iii-stroke-prevention-trial-after-2023-setback 2025-11-23T21:22:23+00:00 hourly 0.9 https://trial.medpath.com/news/black-cumin-seed-shows-promise-for-cholesterol-management-and-fat-cell-inhibition-in-clinical-trial 2025-11-23T17:20:09+00:00 hourly 0.9 https://trial.medpath.com/news/regulatory-t-cell-therapies-advance-through-clinical-development-with-enhanced-monitoring-technologies 2025-11-23T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-bacteriophage-yz2-shows-promise-against-carbapenem-resistant-acinetobacter-baumannii-in-combination-therapy 2025-11-23T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/innocan-pharma-s-cbd-delivery-platform-achieves-28-day-sustained-release-in-regulatory-study 2025-11-23T13:22:04+00:00 hourly 0.9 https://trial.medpath.com/news/trikafta-shows-sustained-anti-inflammatory-effects-in-cystic-fibrosis-patients-through-2-5-years 2025-11-23T09:22:34+00:00 hourly 0.9 https://trial.medpath.com/news/gho-capital-partners-acquires-ai-powered-r-d-platform-scientist-com-to-accelerate-pharmaceutical-research-efficiency 2025-11-23T09:21:46+00:00 hourly 0.9 https://trial.medpath.com/news/erdafitinib-shows-promising-early-efficacy-and-manageable-safety-profile-in-fgfr-tacc-fusion-positive-glioma 2025-11-23T09:21:25+00:00 hourly 0.9 https://trial.medpath.com/news/shilpa-medicare-receives-eight-fda-observations-following-ten-day-inspection-at-jadcherla-manufacturing-facility 2025-11-23T05:20:59+00:00 hourly 0.9 https://trial.medpath.com/news/fda-s-new-drug-chief-pazdur-challenges-commissioner-s-expedited-approval-plans 2025-11-23T01:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/first-in-human-trial-shows-safety-of-intraventricular-her2-car-t-therapy-for-brain-metastases-in-breast-cancer 2025-11-23T01:23:09+00:00 hourly 0.9 https://trial.medpath.com/news/lutetium-lu-177-dotatate-demonstrates-significant-efficacy-in-advanced-intracranial-meningioma-phase-2-trial 2025-11-23T01:23:07+00:00 hourly 0.9 https://trial.medpath.com/news/scientists-identify-rna-molecule-that-may-reverse-als-nerve-damage-in-preclinical-studies 2025-11-23T01:22:41+00:00 hourly 0.9 https://trial.medpath.com/news/oral-arginine-shows-promise-as-cost-effective-alzheimer-s-treatment-in-preclinical-studies 2025-11-22T21:24:58+00:00 hourly 0.9 https://trial.medpath.com/news/ajinomoto-partners-with-forge-biologics-to-double-gene-therapy-manufacturing-productivity 2025-11-22T21:23:29+00:00 hourly 0.9 https://trial.medpath.com/news/cassandra-phase-3-trial-shows-paxg-superior-to-mfolfirinox-in-preoperative-pancreatic-cancer-treatment 2025-11-22T21:21:25+00:00 hourly 0.9 https://trial.medpath.com/news/phase-1-regoma-2-trial-establishes-safe-dosing-for-regorafenib-combination-in-mgmt-methylated-glioblastoma 2025-11-22T17:21:02+00:00 hourly 0.9 https://trial.medpath.com/news/uskudar-university-partners-with-sartorius-to-advance-gene-therapy-and-cell-based-treatment-manufacturing-in-turkey 2025-11-22T17:20:53+00:00 hourly 0.9 https://trial.medpath.com/news/combicor-vax-phase-ii-trial-combines-dendritic-cell-vaccine-with-pembrolizumab-for-refractory-microsatellite-stable-metastatic-colorectal-cancer 2025-11-22T13:20:44+00:00 hourly 0.9 https://trial.medpath.com/news/osr-holdings-subsidiary-vaximm-secures-835m-licensing-deal-for-oral-cancer-immunotherapy-vxm01 2025-11-22T09:20:52+00:00 hourly 0.9 https://trial.medpath.com/news/agc-biologics-partners-with-repair-biotechnologies-to-develop-novel-mrna-therapy-for-cardiovascular-disease 2025-11-22T05:21:57+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-reveals-treatment-gap-in-idh-mutant-glioma-supporting-need-for-early-intervention 2025-11-22T05:21:20+00:00 hourly 0.9 https://trial.medpath.com/news/mirdametinib-achieves-87-response-rate-in-pediatric-low-grade-glioma-phase-1-2-trial 2025-11-22T05:21:15+00:00 hourly 0.9 https://trial.medpath.com/news/long-term-mirdametinib-data-shows-improved-response-rates-and-deeper-tumor-shrinkage-in-nf1-associated-plexiform-neurofibromas 2025-11-22T05:21:06+00:00 hourly 0.9 https://trial.medpath.com/news/immune-checkpoint-inhibitors-show-promise-for-triple-negative-breast-cancer-despite-increased-toxicity-risks 2025-11-22T05:21:04+00:00 hourly 0.9 https://trial.medpath.com/news/praxis-precision-medicines-advances-multiple-neurological-programs-following-essential-tremor-success 2025-11-22T05:20:54+00:00 hourly 0.9 https://trial.medpath.com/news/aston-university-and-comvita-file-patent-for-enhanced-manuka-honey-formulation-against-drug-resistant-bacteria 2025-11-22T05:20:47+00:00 hourly 0.9 https://trial.medpath.com/news/uk-launches-first-clinical-trial-of-puberty-blockers-following-government-ban 2025-11-22T05:19:45+00:00 hourly 0.9 https://trial.medpath.com/news/revive-therapeutics-advances-bucillamine-research-for-nerve-agent-countermeasure-in-collaboration-with-canadian-defense-agency 2025-11-21T21:43:28+00:00 hourly 0.9 https://trial.medpath.com/news/fda-investigates-fatal-adverse-event-linked-to-takeda-s-adzynma-enzyme-replacement-therapy 2025-11-21T21:40:10+00:00 hourly 0.9 https://trial.medpath.com/news/guselkumab-shows-superior-treatment-persistence-over-il-17a-inhibitors-in-psoriatic-arthritis-study 2025-11-21T21:37:18+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-commits-2-billion-to-expand-maryland-manufacturing-operations-doubling-biologics-capacity 2025-11-21T21:36:01+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-and-anaptysbio-file-dueling-lawsuits-over-jemperli-royalty-agreement-as-cancer-drug-nears-blockbuster-status 2025-11-21T21:31:42+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-cincinnati-leads-multicenter-trial-testing-extended-tranexamic-acid-for-acl-surgery-recovery 2025-11-21T21:31:05+00:00 hourly 0.9 https://trial.medpath.com/news/u-s-cell-and-gene-therapy-cdmo-market-set-for-explosive-growth-projected-to-reach-10-34-billion-by-2033 2025-11-21T17:31:36+00:00 hourly 0.9 https://trial.medpath.com/news/five-year-juliet-trial-data-confirms-tisagenlecleucel-as-curative-car-t-therapy-for-relapsed-refractory-large-b-cell-lymphoma 2025-11-21T17:25:31+00:00 hourly 0.9 https://trial.medpath.com/news/polaryx-therapeutics-secures-nasdaq-listing-ahead-of-phase-2-trial-for-rare-lysosomal-storage-disorders 2025-11-21T17:23:13+00:00 hourly 0.9 https://trial.medpath.com/news/northwest-biotherapeutics-begins-construction-of-advanced-grade-c-manufacturing-suite-to-scale-dcvax-production 2025-11-21T17:22:54+00:00 hourly 0.9 https://trial.medpath.com/news/sorcero-raises-42-5m-series-b-to-scale-ai-platform-for-life-sciences-evidence-generation 2025-11-21T17:22:48+00:00 hourly 0.9 https://trial.medpath.com/news/fda-lifts-clinical-hold-on-blue-lake-s-pediatric-rsv-vaccine-trial-allowing-enrollment-of-rsv-negative-toddlers 2025-11-21T17:22:21+00:00 hourly 0.9 https://trial.medpath.com/news/nice-approves-alnylam-s-vutrisiran-for-nhs-use-in-rare-heart-condition-attr-cm 2025-11-21T17:22:01+00:00 hourly 0.9 https://trial.medpath.com/news/waltz-health-launches-industry-first-direct-to-employer-model-for-obesity-medications 2025-11-21T17:21:17+00:00 hourly 0.9 https://trial.medpath.com/news/evofem-s-phexx-advances-toward-uae-approval-as-first-hormone-free-contraceptive-gel 2025-11-21T17:20:35+00:00 hourly 0.9 https://trial.medpath.com/news/contineum-therapeutics-pipe-307-fails-phase-2-multiple-sclerosis-trial 2025-11-21T13:59:04+00:00 hourly 0.9 https://trial.medpath.com/news/bioatla-secures-22-5-million-flexible-financing-to-support-operations-while-pursuing-strategic-partnership 2025-11-21T13:56:12+00:00 hourly 0.9 https://trial.medpath.com/news/crossbridge-bio-secures-15-million-cprit-grant-to-advance-novel-dual-payload-adc-cbb-120-targeting-trop-2 2025-11-21T13:54:22+00:00 hourly 0.9 https://trial.medpath.com/news/meril-s-myval-transcatheter-heart-valve-shows-comparable-one-year-outcomes-to-leading-competitors-in-landmark-trial 2025-11-21T13:53:58+00:00 hourly 0.9 https://trial.medpath.com/news/car-t-cell-therapy-shows-70-reduction-in-atherosclerotic-plaque-in-preclinical-study 2025-11-21T13:53:45+00:00 hourly 0.9 https://trial.medpath.com/news/dicot-pharma-s-lib-01-shows-sustained-erectile-dysfunction-treatment-effects-in-phase-2a-trial 2025-11-21T13:53:12+00:00 hourly 0.9 https://trial.medpath.com/news/cancer-cell-derived-il-1b-identified-as-key-mechanism-reversing-chemo-immunotherapy-resistance-in-nsclc 2025-11-21T13:52:58+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-subsidiary-tesaro-files-lawsuit-against-anaptysbio-over-jemperli-license-breach 2025-11-21T13:51:25+00:00 hourly 0.9 https://trial.medpath.com/news/curatis-secures-chf-1-2-million-to-accelerate-late-stage-corticorelin-development 2025-11-21T13:50:36+00:00 hourly 0.9 https://trial.medpath.com/news/pacbio-gains-china-regulatory-approval-for-clinical-grade-long-read-sequencing-system 2025-11-21T13:50:30+00:00 hourly 0.9 https://trial.medpath.com/news/revir-therapeutics-secures-4-6m-cirm-grant-for-dual-target-huntington-s-disease-therapy 2025-11-21T09:57:41+00:00 hourly 0.9 https://trial.medpath.com/news/onco-innovations-advances-pnkp-inhibitor-manufacturing-scale-up-with-dalton-pharma-for-phase-1-clinical-trials 2025-11-21T09:55:34+00:00 hourly 0.9 https://trial.medpath.com/news/supreme-court-declines-patent-review-case-strengthening-ptab-authority-over-expired-patents 2025-11-21T01:27:45+00:00 hourly 0.9 https://trial.medpath.com/news/actimed-therapeutics-partners-with-mankind-pharma-for-cancer-cachexia-treatment-development-in-south-asia 2025-11-21T01:24:57+00:00 hourly 0.9 https://trial.medpath.com/news/rare-pole-gene-mutation-predicts-strong-immunotherapy-response-in-colorectal-cancer 2025-11-21T01:24:47+00:00 hourly 0.9 https://trial.medpath.com/news/innocan-pharma-s-liposomal-cbd-platform-shows-28-day-sustained-release-in-preclinical-study 2025-11-21T01:23:21+00:00 hourly 0.9 https://trial.medpath.com/news/os-therapies-plans-spinoff-of-animal-health-subsidiary-to-advance-canine-osteosarcoma-treatment 2025-11-21T01:23:12+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-secures-1-5-billion-loan-to-advance-pipeline-beyond-covid-19-vaccines 2025-11-21T01:22:20+00:00 hourly 0.9 https://trial.medpath.com/news/inhibikase-therapeutics-advances-ikt-001-to-global-phase-3-study-for-pulmonary-arterial-hypertension 2025-11-21T01:21:20+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-multiple-new-cancer-therapies-including-bayer-s-hyrnuo-for-nsclc-and-amgen-s-imdelltra-for-small-cell-lung-cancer 2025-11-21T01:21:07+00:00 hourly 0.9 https://trial.medpath.com/news/neurocrine-review-reveals-key-differences-between-fda-approved-tardive-dyskinesia-treatments 2025-11-21T01:21:04+00:00 hourly 0.9 https://trial.medpath.com/news/aurigene-s-malt1-inhibitor-aur112-shows-63-6-response-rate-in-phase-1-lymphoma-trial 2025-11-21T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/samsung-bioepis-explores-organon-acquisition-to-shift-from-partner-based-to-direct-sales-model 2025-11-20T22:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/european-medicines-agency-recommends-approval-for-two-boehringer-ingelheim-avian-flu-vaccines 2025-11-20T21:27:13+00:00 hourly 0.9 https://trial.medpath.com/news/syncromune-s-sync-t-therapy-shows-bone-metastases-resolution-in-phase-1-prostate-cancer-trial 2025-11-20T21:27:11+00:00 hourly 0.9 https://trial.medpath.com/news/mink-therapeutics-reports-preclinical-success-for-mink-215-car-inkt-therapy-in-treatment-resistant-solid-tumors 2025-11-20T21:26:33+00:00 hourly 0.9 https://trial.medpath.com/news/fibrobiologics-secures-regulatory-approval-for-phase-1-2-trial-of-cywc628-in-diabetic-foot-ulcers 2025-11-20T21:24:48+00:00 hourly 0.9 https://trial.medpath.com/news/polymodels-hub-raises-eur7-9m-series-a-to-transform-biopharma-process-development-with-ai-driven-platform 2025-11-20T21:22:33+00:00 hourly 0.9 https://trial.medpath.com/news/mauna-kea-technologies-secures-nmpa-approval-for-next-generation-cellvizio-platform-in-china 2025-11-20T21:22:22+00:00 hourly 0.9 https://trial.medpath.com/news/can-fite-s-cf602-receives-patent-protection-in-brazil-for-novel-erectile-dysfunction-treatment 2025-11-20T17:32:21+00:00 hourly 0.9 https://trial.medpath.com/news/pepromene-bio-s-baffr-car-t-therapy-shows-promising-results-in-relapsed-b-cell-cancers 2025-11-20T17:29:13+00:00 hourly 0.9 https://trial.medpath.com/news/vivac-pharma-appoints-keren-leshem-as-ceo-to-advance-rna-lipid-nanoparticle-cancer-immunotherapy-platform 2025-11-20T17:28:36+00:00 hourly 0.9 https://trial.medpath.com/news/minovia-s-mitochondrial-therapy-shows-promise-in-myelodysplastic-syndrome-phase-1b-trial 2025-11-20T17:25:22+00:00 hourly 0.9 https://trial.medpath.com/news/hitgen-secures-gates-foundation-funding-for-drug-discovery-targeting-tuberculosis-malaria-and-non-hormonal-contraception 2025-11-20T17:23:41+00:00 hourly 0.9 https://trial.medpath.com/news/merck-kgaa-partners-with-valo-health-in-3-billion-ai-driven-parkinson-s-drug-discovery-deal 2025-11-20T17:23:33+00:00 hourly 0.9 https://trial.medpath.com/news/qsimulate-raises-11m-in-seed-funding-launches-quelo-v2-3-quantum-platform-for-peptide-drug-discovery 2025-11-20T17:23:30+00:00 hourly 0.9 https://trial.medpath.com/news/abbott-to-acquire-exact-sciences-for-21-billion-expanding-cancer-diagnostics-portfolio 2025-11-20T17:23:28+00:00 hourly 0.9 https://trial.medpath.com/news/briacell-partners-with-receptor-ai-to-develop-ai-driven-cancer-kinase-inhibitors 2025-11-20T17:22:51+00:00 hourly 0.9 https://trial.medpath.com/news/oncotelic-s-pipeline-receives-1-7-billion-valuation-as-ot-101-advances-to-phase-3-trials 2025-11-20T17:22:09+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-accord-biopharma-s-denosumab-biosimilars-osvyrti-and-jubereq-for-bone-disorders 2025-11-20T17:22:06+00:00 hourly 0.9 https://trial.medpath.com/news/edgewise-therapeutics-strengthens-board-with-commercial-veteran-ahead-of-becker-muscular-dystrophy-launch 2025-11-20T17:22:04+00:00 hourly 0.9 https://trial.medpath.com/news/unige-scientists-develop-dual-target-car-t-cell-therapy-for-treatment-resistant-glioblastoma 2025-11-20T17:21:01+00:00 hourly 0.9 https://trial.medpath.com/news/apoptotic-extracellular-vesicles-emerge-as-novel-biomarkers-for-cancer-and-neurodegenerative-disease-diagnosis 2025-11-20T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-unveils-three-year-growth-strategy-with-expanded-vaccine-portfolio-and-oncology-focus 2025-11-20T13:27:49+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-raises-peak-sales-targets-for-cancer-drugs-kisqali-and-scemblix-forecasts-5-6-annual-growth-through-2030 2025-11-20T13:21:36+00:00 hourly 0.9 https://trial.medpath.com/news/imperial-college-spinout-biocentis-raises-19-million-to-advance-genome-engineered-insect-control-technology 2025-11-20T13:21:28+00:00 hourly 0.9 https://trial.medpath.com/news/quantum-si-advances-proteus-platform-development-with-breakthrough-controlled-cleavage-chemistry-for-protein-sequencing 2025-11-20T13:21:02+00:00 hourly 0.9 https://trial.medpath.com/news/ono-pharmaceutical-secures-approvals-for-braftovi-combination-therapy-in-braf-mutant-colorectal-cancer 2025-11-20T13:20:33+00:00 hourly 0.9 https://trial.medpath.com/news/flagship-pioneering-companies-enter-first-gsk-collaboration-agreements-to-target-respiratory-and-liver-diseases 2025-11-20T13:20:13+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-projects-5-6-annual-growth-through-2030-backed-by-multi-billion-dollar-drug-portfolio 2025-11-20T12:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/french-researchers-develop-novel-mrna-ultrasound-combination-therapy-for-pancreatic-cancer 2025-11-20T09:30:33+00:00 hourly 0.9 https://trial.medpath.com/news/poolbeg-pharma-secures-european-patent-for-polb-001-targeting-severe-influenza-and-cancer-immunotherapy-side-effects 2025-11-20T09:30:30+00:00 hourly 0.9 https://trial.medpath.com/news/nhs-positioned-as-global-innovation-testbed-as-uk-attracts-40-billion-in-technology-investment 2025-11-20T09:14:21+00:00 hourly 0.9 https://trial.medpath.com/news/dexcom-launches-extended-15-day-g7-cgm-system-in-us-and-expands-g7-availability-in-kuwait 2025-11-20T08:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/arch-biopartners-secures-600000-cad-to-advance-kidney-disease-drug-development 2025-11-20T05:21:36+00:00 hourly 0.9 https://trial.medpath.com/news/impact-biotech-reports-73-complete-response-rate-in-phase-3-enlighted-trial-of-padeliporfin-vtp-for-low-grade-utuc 2025-11-20T05:21:27+00:00 hourly 0.9 https://trial.medpath.com/news/surenano-science-enters-letter-of-intent-to-acquire-glp-1-drug-developer-glucapharm 2025-11-20T01:24:58+00:00 hourly 0.9 https://trial.medpath.com/news/checkmate-648-and-keynote-590-establish-chemo-immunotherapy-as-first-line-standard-for-advanced-esophageal-squamous-cell-carcinoma 2025-11-20T01:24:20+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-s-mrna-flu-vaccine-shows-34-5-superior-efficacy-in-phase-3-trial 2025-11-20T01:24:08+00:00 hourly 0.9 https://trial.medpath.com/news/johns-hopkins-researchers-patent-enhanced-mebendazole-formulation-for-cancer-treatment 2025-11-20T01:21:51+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-abbvie-and-genmab-s-epkinly-for-relapsed-or-refractory-follicular-lymphoma 2025-11-20T01:20:23+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-full-approval-to-amgen-s-imdelltra-for-extensive-stage-small-cell-lung-cancer 2025-11-20T01:20:05+00:00 hourly 0.9 https://trial.medpath.com/news/ensysce-biosciences-advances-pf614-phase-3-trial-with-fda-manufacturing-approval-and-extended-patent-protection 2025-11-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/insphero-acquires-doppl-sa-and-sun-bioscience-gri3d-technology-to-create-comprehensive-3d-cell-model-platform 2025-11-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/precise-bio-achieves-world-s-first-3d-bioprinted-corneal-implant-in-human-patient 2025-11-19T21:31:05+00:00 hourly 0.9 https://trial.medpath.com/news/dialectic-therapeutics-initiates-phase-1b-2-trial-of-dt2216-in-platinum-resistant-ovarian-cancer 2025-11-19T21:30:01+00:00 hourly 0.9 https://trial.medpath.com/news/avicanna-s-novel-pwdrx-platform-shows-74-higher-bioavailability-for-cannabinoid-delivery-in-preclinical-studies 2025-11-19T21:25:36+00:00 hourly 0.9 https://trial.medpath.com/news/kaimrc-and-flagship-pioneering-form-70m-partnership-for-genetic-disease-clinical-trials-in-saudi-arabia 2025-11-19T21:25:02+00:00 hourly 0.9 https://trial.medpath.com/news/aperture-therapeutics-advances-cd33-targeting-antisense-oligonucleotide-aprtx-001-for-neurodegenerative-diseases 2025-11-19T21:24:05+00:00 hourly 0.9 https://trial.medpath.com/news/hrv-pharma-and-metrochem-form-strategic-cdmo-partnership-for-high-value-api-development 2025-11-19T21:20:57+00:00 hourly 0.9 https://trial.medpath.com/news/skin-permeable-polymer-delivers-insulin-through-topical-cream-offering-needle-free-diabetes-treatment 2025-11-19T21:20:49+00:00 hourly 0.9 https://trial.medpath.com/news/abbott-laboratories-acquires-exact-sciences-for-21-billion-to-expand-cancer-diagnostics-portfolio 2025-11-19T19:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/new-analysis-reveals-909-immunology-deals-worth-billions-in-biopharma-partnerships-from-2016-2025 2025-11-19T17:31:52+00:00 hourly 0.9 https://trial.medpath.com/news/scynexis-completes-brexafemme-nda-transfer-to-gsk-enabling-antifungal-drug-relaunch 2025-11-19T17:31:42+00:00 hourly 0.9 https://trial.medpath.com/news/rxcelerate-and-constructive-bio-form-strategic-partnership-to-develop-next-generation-biologics-using-programmable-biology-platform 2025-11-19T17:30:38+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-completes-140-million-u-s-manufacturing-expansion-to-enable-full-domestic-mrna-production 2025-11-19T17:30:03+00:00 hourly 0.9 https://trial.medpath.com/news/agios-mitapivat-shows-mixed-results-in-phase-3-sickle-cell-disease-trial 2025-11-19T17:27:43+00:00 hourly 0.9 https://trial.medpath.com/news/respirerx-secures-1-5m-nih-grant-to-advance-novel-epilepsy-treatment-krm-ii-81-toward-clinical-trials 2025-11-19T17:27:34+00:00 hourly 0.9 https://trial.medpath.com/news/novel-gene-therapy-avgn7-2-shows-promising-safety-profile-in-preclinical-study-for-inclusion-body-myositis 2025-11-19T17:27:25+00:00 hourly 0.9 https://trial.medpath.com/news/distalmotion-secures-150m-series-g-to-expand-dexter-surgical-robot-in-u-s-ambulatory-surgery-centers 2025-11-19T17:26:54+00:00 hourly 0.9 https://trial.medpath.com/news/synthio-labs-raises-5-million-to-transform-life-sciences-customer-engagement-with-clinical-voice-ai 2025-11-19T17:26:44+00:00 hourly 0.9 https://trial.medpath.com/news/c-light-technologies-wins-roche-ms-innovation-challenge-to-develop-eye-movement-biomarkers-for-multiple-sclerosis-progression 2025-11-19T17:25:53+00:00 hourly 0.9 https://trial.medpath.com/news/kalivir-partners-with-roche-to-test-novel-oncolytic-immunotherapy-vet3-tgi-in-combination-with-tecentriq 2025-11-19T17:25:50+00:00 hourly 0.9 https://trial.medpath.com/news/olema-pharmaceuticals-stock-falls-7-after-announcing-public-offering-to-fund-breast-cancer-pipeline 2025-11-19T17:25:38+00:00 hourly 0.9 https://trial.medpath.com/news/tempest-therapeutics-acquires-dual-car-t-programs-from-factor-bioscience-in-strategic-all-stock-transaction 2025-11-19T17:25:35+00:00 hourly 0.9 https://trial.medpath.com/news/elicio-therapeutics-appoints-marc-wolfgang-as-cto-to-strengthen-commercial-readiness-for-kras-targeted-cancer-immunotherapy 2025-11-19T17:25:07+00:00 hourly 0.9 https://trial.medpath.com/news/fyr-bio-and-nuvox-therapeutics-secure-1-98m-nci-grant-to-advance-liquid-biopsy-technology-in-glioblastoma-trial 2025-11-19T17:25:01+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-partners-with-nona-biosciences-for-heavy-chain-only-antibody-discovery-platform 2025-11-19T17:24:59+00:00 hourly 0.9 https://trial.medpath.com/news/alzamend-neuro-completes-phase-ii-brain-imaging-study-of-novel-lithium-therapy-al001 2025-11-19T17:24:56+00:00 hourly 0.9 https://trial.medpath.com/news/onepot-ai-emerges-from-stealth-with-13m-to-accelerate-drug-synthesis-using-ai-powered-chemistry 2025-11-19T17:24:25+00:00 hourly 0.9 https://trial.medpath.com/news/india-launches-indigenous-crispr-gene-therapy-birsa-101-for-sickle-cell-disease-targeting-tribal-communities 2025-11-19T17:22:19+00:00 hourly 0.9 https://trial.medpath.com/news/agios-mitapivat-shows-mixed-results-in-sickle-cell-disease-phase-3-trial 2025-11-19T17:21:40+00:00 hourly 0.9 https://trial.medpath.com/news/tara-002-achieves-100-clinical-success-rate-in-phase-2-trial-for-pediatric-lymphatic-malformations 2025-11-19T17:21:13+00:00 hourly 0.9 https://trial.medpath.com/news/dupilumab-demonstrates-superior-2-year-drug-survival-in-atopic-dermatitis-treatment-landscape 2025-11-19T15:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-dexcom-smart-basal-as-first-cgm-integrated-insulin-dosing-optimizer-for-type-2-diabetes 2025-11-19T13:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/profluent-secures-106m-to-advance-ai-driven-protein-design-platform 2025-11-19T13:24:02+00:00 hourly 0.9 https://trial.medpath.com/news/agc-biologics-partners-with-repair-biotechnologies-to-develop-novel-mrna-therapy-for-atherosclerotic-cardiovascular-disease 2025-11-19T13:23:43+00:00 hourly 0.9 https://trial.medpath.com/news/piramal-pharma-solutions-uk-adc-manufacturing-facility-receives-updated-mhra-gmp-certification 2025-11-19T13:21:34+00:00 hourly 0.9 https://trial.medpath.com/news/canon-medical-receives-fda-clearance-for-advanced-interventional-imaging-systems-with-ai-enhanced-technology 2025-11-19T13:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-partners-with-ltz-therapeutics-to-develop-novel-myeloid-cell-engagers-for-cancer-treatment 2025-11-19T09:22:42+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-in-remote-alzheimer-s-testing-finger-prick-blood-samples-enable-global-disease-detection 2025-11-19T09:22:39+00:00 hourly 0.9 https://trial.medpath.com/news/renalytix-s-kidneyintelx-dkd-test-shows-superior-ckd-risk-prediction-in-major-diabetes-care-study 2025-11-19T09:20:40+00:00 hourly 0.9 https://trial.medpath.com/news/first-patient-dosed-with-iv-psilocin-in-groundbreaking-binge-eating-disorder-trial 2025-11-19T09:20:34+00:00 hourly 0.9 https://trial.medpath.com/news/european-budget-impact-study-validates-economic-benefits-of-blue-light-cystoscopy-for-bladder-cancer-diagnosis 2025-11-19T07:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/yoltech-therapeutics-receives-fda-clearance-for-first-pivotal-trial-of-in-vivo-gene-editing-therapy-for-primary-hyperoxaluria-type-1 2025-11-19T05:22:24+00:00 hourly 0.9 https://trial.medpath.com/news/cognito-therapeutics-spectris-device-shows-promise-in-modulating-brain-resilience-pathways-in-alzheimer-s-disease 2025-11-19T05:21:22+00:00 hourly 0.9 https://trial.medpath.com/news/brain-biomarkers-predict-deep-brain-stimulation-success-in-treatment-resistant-depression 2025-11-19T05:21:16+00:00 hourly 0.9 https://trial.medpath.com/news/lynk-pharmaceuticals-topical-jak-inhibitor-lnk01004-shows-promising-phase-ii-results-for-moderate-to-severe-atopic-dermatitis 2025-11-19T05:20:13+00:00 hourly 0.9 https://trial.medpath.com/news/familywell-health-secures-8m-series-a-to-expand-integrated-women-s-mental-health-platform 2025-11-19T01:30:36+00:00 hourly 0.9 https://trial.medpath.com/news/vincere-biosciences-secures-5-million-mjff-grant-to-advance-first-in-class-parkinson-s-usp30-inhibitor-to-clinical-trials 2025-11-19T01:29:52+00:00 hourly 0.9 https://trial.medpath.com/news/vast-therapeutics-alx1-shows-promising-safety-profile-in-phase-1-trial-for-chronic-respiratory-diseases 2025-11-19T01:27:11+00:00 hourly 0.9 https://trial.medpath.com/news/nervgen-pharma-secures-10-million-funding-to-advance-first-in-class-spinal-cord-injury-therapy-nvg-291 2025-11-19T01:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/truth-dkd-trial-compares-tofogliflozin-and-metformin-for-diabetic-kidney-disease-treatment 2025-11-19T01:26:48+00:00 hourly 0.9 https://trial.medpath.com/news/biocytics-achieves-fda-interact-meeting-milestone-for-point-of-care-cell-therapy-platform 2025-11-19T01:26:21+00:00 hourly 0.9 https://trial.medpath.com/news/onco-innovations-partners-with-kuano-to-apply-quantum-computing-to-pnkp-inhibitor-development 2025-11-19T01:25:14+00:00 hourly 0.9 https://trial.medpath.com/news/nature-cell-to-establish-4m-stem-cell-manufacturing-facility-in-baltimore-creating-500-jobs 2025-11-19T01:24:26+00:00 hourly 0.9 https://trial.medpath.com/news/three-year-izervay-data-shows-sustained-reduction-in-geographic-atrophy-lesion-growth 2025-11-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/alector-s-late-stage-frontotemporal-dementia-drug-fails-phase-iii-trial-company-cuts-workforce-by-49 2025-11-18T21:27:06+00:00 hourly 0.9 https://trial.medpath.com/news/federal-circuit-invalidates-39-million-hair-loss-drug-patent-in-sandoz-victory 2025-11-18T21:26:31+00:00 hourly 0.9 https://trial.medpath.com/news/invenirex-secures-ps2m-to-commercialize-revolutionary-dna-nanotechnology-platform-for-ultra-early-disease-detection 2025-11-18T21:25:16+00:00 hourly 0.9 https://trial.medpath.com/news/eve-bio-and-drugbank-partner-to-integrate-record-scale-pharmome-mapping-data-into-drug-discovery-platform 2025-11-18T21:24:07+00:00 hourly 0.9 https://trial.medpath.com/news/metformin-fails-to-delay-progression-in-low-risk-prostate-cancer-active-surveillance 2025-11-18T21:23:49+00:00 hourly 0.9 https://trial.medpath.com/news/arrowhead-pharmaceuticals-secures-first-fda-approval-with-redemplo-for-rare-genetic-disorder 2025-11-18T21:20:23+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-sirna-therapy-plozasiran-for-rare-metabolic-disorder-familial-chylomicronemia-syndrome 2025-11-18T21:20:20+00:00 hourly 0.9 https://trial.medpath.com/news/nice-approves-talquetamab-for-nhs-use-offering-new-hope-for-multiple-myeloma-patients 2025-11-18T21:20:18+00:00 hourly 0.9 https://trial.medpath.com/news/oxford-and-gsk-launch-ps50-million-partnership-to-advance-cancer-prevention-and-inflammatory-disease-research 2025-11-18T21:19:43+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-seeks-to-strike-amgen-s-patent-counterclaims-in-aflibercept-biosimilar-litigation 2025-11-18T19:55:00+00:00 hourly 0.9 https://trial.medpath.com/news/arcera-life-sciences-launches-breakthrough-antibiotic-in-uae-to-combat-antimicrobial-resistance 2025-11-18T18:23:00+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-approves-nilemdo-for-ldl-cholesterol-reduction-in-cardiovascular-disease-patients 2025-11-18T17:36:15+00:00 hourly 0.9 https://trial.medpath.com/news/vyome-holdings-reports-positive-phase-2-results-for-vt-1953-in-malignant-fungating-wounds 2025-11-18T17:35:05+00:00 hourly 0.9 https://trial.medpath.com/news/clairity-secures-43m-series-b-to-commercialize-first-fda-authorized-ai-platform-for-breast-cancer-risk-prediction 2025-11-18T17:35:02+00:00 hourly 0.9 https://trial.medpath.com/news/inmed-s-alzheimer-s-drug-candidate-inm-901-shows-favorable-bioavailability-in-large-animal-studies 2025-11-18T17:33:41+00:00 hourly 0.9 https://trial.medpath.com/news/singapore-researchers-develop-rna-therapy-targeting-undruggable-kras-cancer-gene 2025-11-18T17:33:35+00:00 hourly 0.9 https://trial.medpath.com/news/thermo-fisher-scientific-opens-east-coast-advanced-therapies-collaboration-center-to-accelerate-cell-and-gene-therapy-development 2025-11-18T17:32:56+00:00 hourly 0.9 https://trial.medpath.com/news/hermes-biosciences-secures-seed-funding-to-advance-extracellular-vesicle-isolation-technology-for-precision-medicine 2025-11-18T17:32:18+00:00 hourly 0.9 https://trial.medpath.com/news/zymeworks-pivots-to-royalty-driven-model-following-ziihera-s-late-stage-success-in-gastroesophageal-cancer 2025-11-18T17:31:32+00:00 hourly 0.9 https://trial.medpath.com/news/brazilian-researchers-identify-amazon-scorpion-venom-peptide-with-promising-anti-breast-cancer-activity 2025-11-18T17:29:52+00:00 hourly 0.9 https://trial.medpath.com/news/radiopharm-theranostics-receives-ethics-approval-for-first-in-human-trial-of-rad-402-in-advanced-prostate-cancer 2025-11-18T17:29:47+00:00 hourly 0.9 https://trial.medpath.com/news/mabloc-and-instituto-butantan-partner-to-develop-first-in-class-monoclonal-antibody-therapy-for-yellow-fever 2025-11-18T17:29:44+00:00 hourly 0.9 https://trial.medpath.com/news/federal-circuit-upholds-patent-invalidation-of-merck-s-oral-cladribine-ms-treatment-regimen 2025-11-18T17:28:45+00:00 hourly 0.9 https://trial.medpath.com/news/hcw-biologics-initiates-first-in-human-trial-of-il-2-fusion-therapy-hcw9302-for-alopecia-areata 2025-11-18T17:28:17+00:00 hourly 0.9 https://trial.medpath.com/news/quanterix-validates-dual-blood-biomarker-test-for-comprehensive-multiple-sclerosis-monitoring 2025-11-18T17:27:58+00:00 hourly 0.9 https://trial.medpath.com/news/csl-announces-1-5-billion-u-s-investment-to-expand-plasma-derived-therapy-manufacturing 2025-11-18T17:27:32+00:00 hourly 0.9 https://trial.medpath.com/news/hepatitis-c-pricing-wars-of-2014-offer-blueprint-for-current-glp-1-obesity-drug-competition 2025-11-18T17:27:17+00:00 hourly 0.9 https://trial.medpath.com/news/tivic-health-secures-barda-meeting-to-advance-entolimod-for-acute-radiation-syndrome 2025-11-18T17:25:13+00:00 hourly 0.9 https://trial.medpath.com/news/kangpu-s-novel-cereblon-modulator-shows-50-response-rate-in-heavily-pre-treated-multiple-myeloma-patients 2025-11-18T17:25:07+00:00 hourly 0.9 https://trial.medpath.com/news/vanda-s-tradipitant-reduces-glp-1-induced-vomiting-by-50-in-phase-2-trial 2025-11-18T17:24:12+00:00 hourly 0.9 https://trial.medpath.com/news/can-fite-reports-9-year-complete-response-in-advanced-liver-cancer-patient-as-phase-iii-trial-enrolls 2025-11-18T17:23:54+00:00 hourly 0.9 https://trial.medpath.com/news/bionet-s-vacpertagen-receives-positive-ema-opinion-as-first-standalone-pertussis-vaccine-in-eu 2025-11-18T17:23:12+00:00 hourly 0.9 https://trial.medpath.com/news/uk-launches-ps18-8-million-initiative-to-transform-nuclear-waste-into-precision-cancer-therapies 2025-11-18T17:23:07+00:00 hourly 0.9 https://trial.medpath.com/news/nanopath-receives-fda-breakthrough-device-designation-for-point-of-care-molecular-uti-diagnostic-platform 2025-11-18T17:22:23+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-antithrombin-concentrate-for-pediatric-patients-with-hereditary-antithrombin-deficiency 2025-11-18T17:22:21+00:00 hourly 0.9 https://trial.medpath.com/news/cryotherapeutics-launches-icecap-trial-combining-cryotherapy-with-ai-powered-imaging-to-target-high-risk-coronary-plaques 2025-11-18T17:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/advocate-health-launches-nation-s-largest-clinical-trial-network-to-democratize-access-to-breakthrough-treatments 2025-11-18T17:21:02+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-bispecific-antibody-combination-for-relapsed-refractory-follicular-lymphoma 2025-11-18T17:20:31+00:00 hourly 0.9 https://trial.medpath.com/news/mro-acquires-ai-driven-clinical-trial-recruitment-platform-clinetic-to-streamline-patient-enrollment 2025-11-18T17:20:28+00:00 hourly 0.9 https://trial.medpath.com/news/cellbyte-secures-2-75m-to-accelerate-drug-launch-timelines-with-ai-platform 2025-11-18T17:20:01+00:00 hourly 0.9 https://trial.medpath.com/news/dual-pd-1-ctla-4-immunotherapy-shows-promise-in-ovarian-cancer-treatment 2025-11-18T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/multiple-sclerosis-patients-show-preserved-covid-19-vaccine-responses-despite-disease-modifying-therapies 2025-11-18T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-opens-consultation-on-decentralized-clinical-trials-guidance-as-global-regulatory-frameworks-converge 2025-11-18T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/european-commission-approves-world-s-first-liquid-formulation-of-iv-infliximab-promising-significant-cost-savings 2025-11-18T13:25:28+00:00 hourly 0.9 https://trial.medpath.com/news/emulate-and-fujifilm-launch-brain-chip-r1-to-overcome-blood-brain-barrier-challenges-in-cns-drug-development 2025-11-18T13:22:04+00:00 hourly 0.9 https://trial.medpath.com/news/avanzanite-secures-eur32m-series-a-to-scale-rare-disease-drug-access-across-europe 2025-11-18T13:20:50+00:00 hourly 0.9 https://trial.medpath.com/news/medicinova-strengthens-leadership-with-fda-veteran-dr-christopher-breder-as-clinical-and-regulatory-advisor 2025-11-18T13:20:21+00:00 hourly 0.9 https://trial.medpath.com/news/koru-medical-submits-fda-510-k-application-for-freedomedge-infusion-system-with-oncology-biologic-phesgo 2025-11-18T11:37:00+00:00 hourly 0.9 https://trial.medpath.com/news/federal-circuit-overturns-39-million-jury-verdict-invalidates-allergan-hair-loss-patent-for-inadequate-written-description 2025-11-18T10:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/ubivac-s-dpv-001-cancer-vaccine-shows-3x-response-rate-improvement-in-head-and-neck-cancer-trial 2025-11-18T09:21:49+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-and-fleming-initiative-launch-ps45m-ai-powered-research-program-to-combat-antimicrobial-resistance 2025-11-18T09:21:22+00:00 hourly 0.9 https://trial.medpath.com/news/biomx-secures-3-0-million-private-placement-to-advance-bacteriophage-therapies-for-bacterial-infections 2025-11-18T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/mainz-biomed-achieves-100-sensitivity-in-pancreatic-cancer-blood-test-feasibility-study 2025-11-18T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sonoma-biotherapeutics-appoints-new-ceo-following-positive-treg-therapy-trial-results 2025-11-18T05:23:55+00:00 hourly 0.9 https://trial.medpath.com/news/high-immune-infiltration-predicts-worse-outcomes-in-bevacizumab-treated-ovarian-cancer-patients 2025-11-18T05:21:16+00:00 hourly 0.9 https://trial.medpath.com/news/genesis-medtech-and-national-university-health-system-launch-four-year-ai-partnership-to-transform-surgical-care 2025-11-18T05:20:12+00:00 hourly 0.9 https://trial.medpath.com/news/70-year-old-blood-pressure-drug-hydralazine-shows-promise-against-aggressive-brain-tumors 2025-11-18T05:19:57+00:00 hourly 0.9 https://trial.medpath.com/news/microdose-cannabis-extract-shows-promise-in-slowing-cognitive-decline-in-alzheimer-s-patients 2025-11-18T03:47:00+00:00 hourly 0.9 https://trial.medpath.com/news/art-501-shows-promise-in-phase-2a-trial-for-autism-spectrum-disorder-treatment 2025-11-18T01:24:05+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-acquires-halda-therapeutics-for-3-05-billion-to-strengthen-oncology-pipeline 2025-11-18T01:23:33+00:00 hourly 0.9 https://trial.medpath.com/news/cincinnati-children-s-opens-expanded-gene-and-cell-therapy-manufacturing-center-to-accelerate-clinical-trials 2025-11-18T01:21:58+00:00 hourly 0.9 https://trial.medpath.com/news/terray-therapeutics-achieves-drug-discovery-milestone-with-bristol-myers-squibb-using-ai-native-emmi-platform 2025-11-18T01:21:17+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-komzifti-as-first-once-daily-oral-menin-inhibitor-for-relapsed-npm1-mutated-aml 2025-11-18T01:20:46+00:00 hourly 0.9 https://trial.medpath.com/news/federal-judge-approves-purdue-pharma-s-7-4-billion-opioid-settlement 2025-11-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/aclipse-therapeutics-partners-with-mayo-clinic-for-phase-2-trial-of-first-disease-modifying-gastroparesis-treatment 2025-11-17T21:33:04+00:00 hourly 0.9 https://trial.medpath.com/news/dry-amd-market-set-for-significant-growth-through-2034-as-novel-therapies-advance-in-clinical-development 2025-11-17T21:32:29+00:00 hourly 0.9 https://trial.medpath.com/news/scynexis-secures-35-million-nih-grant-to-advance-next-generation-antifungal-therapeutics 2025-11-17T21:32:24+00:00 hourly 0.9 https://trial.medpath.com/news/protara-therapeutics-to-present-phase-2-tara-002-data-for-bcg-naive-bladder-cancer-patients-at-suo-meeting 2025-11-17T21:31:36+00:00 hourly 0.9 https://trial.medpath.com/news/azurity-pharmaceuticals-acquires-sebela-s-bowel-prep-franchise-as-sebela-advances-gerd-drug-tegoprazan-to-fda-submission 2025-11-17T21:30:27+00:00 hourly 0.9 https://trial.medpath.com/news/raphael-pharmaceutical-files-patent-for-thc-free-cannabinoid-therapy-targeting-rheumatoid-arthritis 2025-11-17T21:28:59+00:00 hourly 0.9 https://trial.medpath.com/news/delhi-high-court-allows-natco-pharma-to-continue-cyantraniliprole-insecticide-sales-despite-fmc-patent-dispute 2025-11-17T21:28:48+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-and-sun-pharma-partner-to-expand-access-to-hyperkalaemia-treatment-in-india 2025-11-17T21:26:27+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-s-lupron-depot-receives-health-canada-approval-for-new-6-month-dosing-option-in-advanced-prostate-cancer 2025-11-17T21:26:24+00:00 hourly 0.9 https://trial.medpath.com/news/nerivio-wearable-device-shows-no-tachyphylaxis-in-3-year-migraine-study 2025-11-17T21:24:59+00:00 hourly 0.9 https://trial.medpath.com/news/is4s-secures-direct-to-phase-ii-sbir-contract-for-advanced-fireset-system-development 2025-11-17T21:23:34+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-perjeta-biosimilar-as-shanghai-henlius-and-organon-secure-interchangeable-status 2025-11-17T21:22:34+00:00 hourly 0.9 https://trial.medpath.com/news/nih-grant-terminations-disrupt-383-clinical-trials-affecting-over-74000-participants 2025-11-17T21:22:31+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-gene-editing-reverses-chemotherapy-resistance-in-lung-cancer-by-targeting-nrf2 2025-11-17T21:22:19+00:00 hourly 0.9 https://trial.medpath.com/news/liquidia-s-yutrepia-achieves-commercial-success-with-51-7m-q3-sales-attracting-major-biotech-fund-investment 2025-11-17T21:20:13+00:00 hourly 0.9 https://trial.medpath.com/news/imbria-pharmaceuticals-secures-extended-series-b-funding-to-advance-first-in-class-cardiovascular-therapy-ninerafaxstat 2025-11-17T17:35:58+00:00 hourly 0.9 https://trial.medpath.com/news/4d-molecular-therapeutics-appoints-kristian-humer-as-cfo-as-company-advances-phase-iii-retinal-disease-programs 2025-11-17T17:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/omeros-secures-240m-novo-nordisk-deal-as-narsoplimab-approaches-fda-approval-for-tatma 2025-11-17T17:34:55+00:00 hourly 0.9 https://trial.medpath.com/news/profluent-bio-partners-with-rsrt-to-develop-ai-designed-gene-editors-for-rett-syndrome 2025-11-17T17:30:43+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-slashes-wegovy-and-ozempic-prices-for-cash-paying-patients 2025-11-17T17:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/acumen-pharmaceuticals-initiates-open-label-extension-study-for-alzheimer-s-drug-sabirnetug 2025-11-17T17:28:41+00:00 hourly 0.9 https://trial.medpath.com/news/acuitas-therapeutics-advances-next-generation-lipid-nanoparticle-technology-with-enhanced-potency-and-targeted-delivery 2025-11-17T17:27:15+00:00 hourly 0.9 https://trial.medpath.com/news/recode-therapeutics-advances-phase-2-trial-of-inhaled-cftr-mrna-therapy-rct2100-combined-with-ivacaftor-for-cystic-fibrosis 2025-11-17T17:27:13+00:00 hourly 0.9 https://trial.medpath.com/news/masimo-wins-634-million-patent-verdict-against-apple-over-heart-rate-monitoring-technology 2025-11-17T17:27:08+00:00 hourly 0.9 https://trial.medpath.com/news/angiex-raises-31-million-to-advance-first-in-class-nuclear-delivered-adc-agx101-through-phase-1-trial 2025-11-17T17:25:54+00:00 hourly 0.9 https://trial.medpath.com/news/oceanic-stroke-phase-3-trial-advances-factor-xia-inhibitor-asundexian-for-secondary-stroke-prevention 2025-11-17T17:25:38+00:00 hourly 0.9 https://trial.medpath.com/news/biotheryx-completes-enrollment-in-phase-1a-trial-of-first-in-class-cdk4-6-degrader-btx-9341-for-hr-her2-breast-cancer 2025-11-17T17:25:06+00:00 hourly 0.9 https://trial.medpath.com/news/broken-string-biosciences-appoints-new-ceo-to-commercialize-gene-editing-safety-platform 2025-11-17T17:24:48+00:00 hourly 0.9 https://trial.medpath.com/news/artios-pharma-raises-115m-series-d-to-advance-dna-damage-response-cancer-therapies 2025-11-17T17:24:22+00:00 hourly 0.9 https://trial.medpath.com/news/biolinerx-secures-key-patent-for-glix1-cancer-therapy-covering-over-90-of-cancer-types 2025-11-17T17:24:03+00:00 hourly 0.9 https://trial.medpath.com/news/ohio-state-university-launches-400000-psychedelic-crisis-training-program-for-healthcare-professionals 2025-11-17T17:23:49+00:00 hourly 0.9 https://trial.medpath.com/news/adaptimmune-undergoes-major-leadership-restructuring-following-nasdaq-delisting-and-asset-divestiture 2025-11-17T17:23:14+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-acquires-halda-therapeutics-for-3-05-billion-to-strengthen-cancer-pipeline 2025-11-17T17:22:03+00:00 hourly 0.9 https://trial.medpath.com/news/scottish-brain-sciences-opens-third-clinical-research-center-in-aberdeen-to-advance-alzheimer-s-early-detection-studies 2025-11-17T17:22:01+00:00 hourly 0.9 https://trial.medpath.com/news/artios-pharma-raises-115m-series-d-to-advance-next-generation-dna-damage-repair-cancer-therapies 2025-11-17T17:21:58+00:00 hourly 0.9 https://trial.medpath.com/news/pluristyx-secures-1-4m-from-breakthrough-t1d-to-develop-universal-immune-cloaked-cell-line-for-type-1-diabetes-therapies 2025-11-17T17:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/biorestorative-secures-fda-type-b-meeting-to-discuss-accelerated-approval-pathway-for-brtx-100-stem-cell-therapy 2025-11-17T17:20:05+00:00 hourly 0.9 https://trial.medpath.com/news/merus-and-halozyme-partner-to-develop-subcutaneous-formulation-of-petosemtamab-for-cancer-treatment 2025-11-17T17:19:41+00:00 hourly 0.9 https://trial.medpath.com/news/who-approves-international-name-for-anixa-s-novel-car-t-therapy-targeting-ovarian-cancer 2025-11-17T17:19:26+00:00 hourly 0.9 https://trial.medpath.com/news/ema-launches-streamlined-process-to-fast-track-critical-medicines-and-vaccines-for-public-health-threats 2025-11-17T17:19:21+00:00 hourly 0.9 https://trial.medpath.com/news/galmed-reports-promising-triple-drug-combination-for-gastrointestinal-cancers 2025-11-17T17:18:14+00:00 hourly 0.9 https://trial.medpath.com/news/solve-therapeutics-secures-120-million-to-advance-next-generation-adc-platform-for-solid-tumors 2025-11-17T17:18:12+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-launches-cgrp-receptor-antagonist-rimegepant-for-migraine-treatment-in-india 2025-11-17T17:18:09+00:00 hourly 0.9 https://trial.medpath.com/news/eu-funded-transcan-3-project-advances-personalized-t-cell-therapy-for-esophageal-cancer 2025-11-17T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/nxera-pharma-announces-strategic-restructuring-with-15-workforce-reduction-to-focus-on-gpcr-pipeline 2025-11-17T13:24:30+00:00 hourly 0.9 https://trial.medpath.com/news/accession-therapeutics-doses-first-patient-in-phase-1-trial-of-novel-tumor-activated-viral-immunotherapy-trocept-01 2025-11-17T13:23:52+00:00 hourly 0.9 https://trial.medpath.com/news/itm-receives-fda-fast-track-designation-for-itm-94-diagnostic-agent-in-clear-cell-renal-cell-carcinoma 2025-11-17T13:21:07+00:00 hourly 0.9 https://trial.medpath.com/news/ziihera-demonstrates-superior-efficacy-in-phase-3-trial-for-her2-positive-gastroesophageal-cancer 2025-11-17T13:20:33+00:00 hourly 0.9 https://trial.medpath.com/news/switching-from-ibrutinib-to-zanubrutinib-maintains-efficacy-and-safety-in-waldenstrom-macroglobulinemia-patients 2025-11-17T13:19:49+00:00 hourly 0.9 https://trial.medpath.com/news/world-s-first-lung-cancer-prevention-vaccine-lungvax-receives-ps2-06-million-for-phase-i-clinical-trial 2025-11-17T13:19:44+00:00 hourly 0.9 https://trial.medpath.com/news/kazakhstan-s-anti-cancer-drug-targeting-kras-mutant-tumors-advances-to-phase-2026-clinical-trials 2025-11-17T13:19:38+00:00 hourly 0.9 https://trial.medpath.com/news/captain-t-cell-secures-eur20-million-to-advance-next-generation-tcr-t-therapies-for-solid-tumors 2025-11-17T09:22:28+00:00 hourly 0.9 https://trial.medpath.com/news/agomab-s-ontunisertib-achieves-primary-safety-endpoint-in-first-in-class-phase-2a-trial-for-fibrostenosing-crohn-s-disease 2025-11-17T09:21:46+00:00 hourly 0.9 https://trial.medpath.com/news/ybrain-launches-enhanced-at-home-electronic-depression-treatment-device-with-62-8-remission-rate 2025-11-17T09:21:24+00:00 hourly 0.9 https://trial.medpath.com/news/sandoz-launches-first-fda-approved-multiple-sclerosis-biosimilar-tyruko-in-us-market 2025-11-17T09:20:55+00:00 hourly 0.9 https://trial.medpath.com/news/european-regulators-recommend-approval-of-incyte-s-minjuvi-for-relapsed-follicular-lymphoma 2025-11-17T09:19:44+00:00 hourly 0.9 https://trial.medpath.com/news/formycon-achieves-technical-proof-of-similarity-for-dupilumab-biosimilar-fyb208-targeting-20-billion-market 2025-11-17T09:19:41+00:00 hourly 0.9 https://trial.medpath.com/news/nice-initiates-appraisals-for-two-cancer-immunotherapies-sasanlimab-bcg-combination-and-cemiplimab-adjuvant-treatment 2025-11-17T08:55:00+00:00 hourly 0.9 https://trial.medpath.com/news/wellscare-expands-iaso-wearable-cold-laser-therapy-to-thailand-through-strategic-partnership 2025-11-17T05:20:07+00:00 hourly 0.9 https://trial.medpath.com/news/bioxyne-secures-1-7m-scottish-government-funding-to-establish-uk-medicinal-cannabis-manufacturing-facility 2025-11-17T05:19:06+00:00 hourly 0.9 https://trial.medpath.com/news/spravato-receives-fda-approval-as-first-monotherapy-for-treatment-resistant-depression 2025-11-17T05:18:41+00:00 hourly 0.9 https://trial.medpath.com/news/golexanolone-shows-promise-as-early-disease-modifying-treatment-for-parkinson-s-disease 2025-11-17T03:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/annovis-bio-s-buntanetap-halts-cognitive-decline-in-parkinson-s-patients-shows-strongest-effect-in-amyloid-co-pathology-subgroup 2025-11-17T02:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/korean-biotech-platforms-drive-record-13-5-billion-in-technology-exports 2025-11-17T01:19:43+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-cas9-gene-editing-shows-promise-for-treating-collagen-disorders 2025-11-17T01:18:57+00:00 hourly 0.9 https://trial.medpath.com/news/pharmather-secures-exclusive-rights-to-long-acting-injectable-ketamine-technology-for-treatment-resistant-depression 2025-11-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/pulsed-field-ablation-demonstrates-superior-efficacy-and-safety-profile-in-landmark-sham-controlled-trial-and-real-world-registry 2025-11-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/epirium-bio-gains-fda-alignment-for-phase-2b-trial-of-first-in-class-sarcopenia-treatment-mf-300 2025-11-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ivonescimab-receives-china-approval-for-egfr-mutated-nsclc-demonstrates-superior-efficacy-across-multiple-cancer-types 2025-11-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/duke-health-reports-100-survival-rate-in-20-year-breast-cancer-vaccine-trial 2025-11-16T17:19:39+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-accelerated-approval-for-elevidys-gene-therapy-first-treatment-for-duchenne-muscular-dystrophy 2025-11-16T17:18:16+00:00 hourly 0.9 https://trial.medpath.com/news/tumor-infiltrating-lymphocyte-therapy-shows-promise-in-advanced-melanoma-with-sustained-response-rates 2025-11-16T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/zhongsheng-pharmaceutical-advances-pediatric-angladivir-granules-to-phase-iii-for-influenza-a-treatment 2025-11-16T13:21:27+00:00 hourly 0.9 https://trial.medpath.com/news/cdsco-orders-dr-reddy-s-to-revise-vonoprazan-phase-iv-trial-protocol-over-inadequate-sample-size 2025-11-16T09:19:45+00:00 hourly 0.9 https://trial.medpath.com/news/aav-delivered-sirna-therapy-shows-promise-for-targeting-mucus-overproduction-in-asthma 2025-11-16T09:19:40+00:00 hourly 0.9 https://trial.medpath.com/news/obagi-medical-presents-pivotal-hyaluronic-acid-filler-data-at-asds-meeting-demonstrating-non-inferiority-to-juvederm-voluma 2025-11-16T09:18:55+00:00 hourly 0.9 https://trial.medpath.com/news/pharvaris-reports-92-4-reduction-in-hereditary-angioedema-attacks-with-deucrictibant-in-long-term-study 2025-11-16T05:19:31+00:00 hourly 0.9 https://trial.medpath.com/news/engineered-aav-variants-show-10-fold-improvement-in-vascular-gene-delivery 2025-11-16T01:19:43+00:00 hourly 0.9 https://trial.medpath.com/news/nad-supplement-shows-early-promise-for-long-covid-fatigue-and-brain-fog-in-clinical-trial 2025-11-16T01:19:38+00:00 hourly 0.9 https://trial.medpath.com/news/brainxell-s-bxt-110-shows-promising-preclinical-results-for-parkinson-s-disease-cell-therapy 2025-11-16T01:19:35+00:00 hourly 0.9 https://trial.medpath.com/news/facet-life-sciences-and-xcancer-form-strategic-partnership-to-accelerate-theranostic-drug-development 2025-11-16T01:19:22+00:00 hourly 0.9 https://trial.medpath.com/news/maxx-orthopedics-secures-fda-clearance-for-two-advanced-orthopedic-implant-systems 2025-11-16T01:19:19+00:00 hourly 0.9 https://trial.medpath.com/news/curevac-reports-eur371-6-million-net-income-following-gsk-partnership-and-strategic-restructuring 2025-11-15T21:21:45+00:00 hourly 0.9 https://trial.medpath.com/news/fda-rejects-uniqure-s-amt-130-gene-therapy-data-for-huntington-s-disease-bla-submission 2025-11-15T21:21:06+00:00 hourly 0.9 https://trial.medpath.com/news/mangoceuticals-launches-direct-access-programs-for-zepbound-and-wegovy-through-eli-lilly-and-novo-nordisk-partnerships 2025-11-15T17:21:43+00:00 hourly 0.9 https://trial.medpath.com/news/trinity-biotech-partners-with-bioinformatics-company-to-advance-epicapture-prostate-cancer-test 2025-11-15T17:20:20+00:00 hourly 0.9 https://trial.medpath.com/news/curis-to-present-emavusertib-clinical-data-in-cns-lymphoma-at-society-for-neuro-oncology-meeting 2025-11-15T13:23:07+00:00 hourly 0.9 https://trial.medpath.com/news/gates-foundation-awards-13-5-million-to-slash-monoclonal-antibody-costs-from-100-to-10-per-gram 2025-11-15T13:21:51+00:00 hourly 0.9 https://trial.medpath.com/news/tb-alliance-to-present-phase-2-results-for-sorfequiline-next-generation-tb-drug-candidate 2025-11-15T09:31:33+00:00 hourly 0.9 https://trial.medpath.com/news/trevi-therapeutics-advances-chronic-cough-drug-haduvio-toward-phase-3-trials-with-extended-cash-runway-through-2028 2025-11-15T09:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/gate-bioscience-raises-65-million-series-b-to-advance-novel-oral-molecular-gate-therapies-into-clinical-trials 2025-11-15T05:20:54+00:00 hourly 0.9 https://trial.medpath.com/news/windtree-therapeutics-strengthens-patent-portfolio-for-heart-failure-drug-istaroxime-with-international-approvals 2025-11-15T05:20:47+00:00 hourly 0.9 https://trial.medpath.com/news/biomimetic-mrna-delivery-system-achieves-20-fold-improvement-in-tumor-targeting-for-colorectal-cancer 2025-11-15T05:20:13+00:00 hourly 0.9 https://trial.medpath.com/news/repare-therapeutics-agrees-to-1-82-per-share-acquisition-by-xenotherapeutics 2025-11-15T01:27:23+00:00 hourly 0.9 https://trial.medpath.com/news/curative-surgery-after-immunotherapy-reduces-death-risk-by-85-in-advanced-liver-cancer 2025-11-15T01:23:14+00:00 hourly 0.9 https://trial.medpath.com/news/magnetic-nanoparticles-enhance-amphotericin-b-delivery-against-leishmaniasis-with-reduced-toxicity 2025-11-15T01:21:40+00:00 hourly 0.9 https://trial.medpath.com/news/enzymit-and-cosun-achieve-world-s-first-pilot-scale-cell-free-hyaluronic-acid-production 2025-11-15T01:20:29+00:00 hourly 0.9 https://trial.medpath.com/news/orasis-pharmaceuticals-expands-qlosi-access-with-new-starter-packs-following-strong-market-adoption 2025-11-14T21:26:17+00:00 hourly 0.9 https://trial.medpath.com/news/biotron-s-bit-hbv001-shows-superior-antiviral-activity-against-hepatitis-b-compared-to-standard-therapy 2025-11-14T21:25:35+00:00 hourly 0.9 https://trial.medpath.com/news/revolutionary-car-t-therapy-shows-promise-for-autoimmune-disease-treatment 2025-11-14T17:32:50+00:00 hourly 0.9